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1. Introduction  
The identification, prevention, and clinical solution of drug interactions (DIs) are a critical 
aspect to achieve desired pharmacotherapy goals in patients infected with human 
immunodeficiency virus and/or affected by acquired immunodeficiency syndrome 
(HIV/AIDS) receiving antiretroviral (ARV) therapy, mainly because DIs may lead that ARV 
therapy will be unsafe and/or ineffective and thus, DIs may be clinical relevant. 
Additionally, in this group of patients the DIs are more frequent among other aspects by:  
 The use of Highly Active Antiretroviral Therapy (HAART) or combined Antiretroviral 
Therapy (cART) includes three or more ARV drugs; (DHHS, 2011) therefore it is 
associated with a greater likelihood of DIs. 
 The pharmacokinetic properties of ARV drugs, for instance several of them are 
metabolized through complimentary cytochrome P450 isoenzymes, thus their 
therapeutic use could be accompanied by frequent DIs. (Miller et al., 2007)  
 ARV drugs are concurrently used with other class of medications for other common 
conditions, mainly infections and cardiovascular disease; and many of these 
medications used to treat these conditions are metabolized through complimentary 
cytochrome P450 isoenzymes, so several pharmacokinetic DIs may occur.  
Accordingly, some studies illustrate that the 96% of patients receiving HAART or cART has 
at least a clinical condition or use a concomitant drug that could cause that ARV therapy 
may be unsafe (adverse drug reactions) or ineffectiveness (therapeutic failure). (Grimes et 
al., 30 2002) Therefore, identifying, preventing, and solving clinically relevant DIs is 
recognized both as a topic of great importance in achieving therapeutic goals for drug 
therapy (Kashuba, 2005) as a constant challenge to health care providers to HIV-infected 
patients receiving HAAR or cART. In addition, the clinical significance of a DI depends on 
the disposition and toxicity profile of the drug being administered. Thus, in HIV-infected 
patients assessing the clinical relevance of a DI is complex due to the large interpatient 
variability in pharmacokinetics exhibited by most ARV drugs, and then the evaluation and 
prediction of clinical effect of a DI is critical in the pharmacotherapy of patients with 
HIV/AIDS. 
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Since most of ARV drug DIs are clinically relevant, it is considered appropriate both to 
outline the concept, types, mechanisms, and effects of ARV DIs on drug therapy, and to 
present a comprehensive summary of those drugs that are affected and the clinical 
relevance of ARV DIs. In this way, the aim of this chapter is provide evidence and 
systematize information about DIs in HIV-infected receiving ART therapy, which allow 
define, evaluate, and predict the clinical relevance of the DIs, highlight those associated to 
pharmacokinetic mechanism. In this way, a proposal to identify, evaluate, and predict DIs 
considered as clinically relevant is presented, in which clinical relevance of a DI is defined 
according to the probability of their occurrence and to the severity of clinical effect in patient 
health (adverse event or therapeutic failure). (Amariles et al., 2007a) 
Previous review about DIs with ARV, (Amariles et al., 2007b; Giraldo et al., 2010) achieved 
as a result of searched in Pubmed/Medline database, have showed that, in the case of 
clinically relevant pharmacokinetic interactions, nearly 80% are related to changes in 
systemic clearance, mainly associated to the systemic inhibition or induction of the 
metabolic activity of the cytochrome P-450 (CYP-450), mostly CYP3A4 isoform, whereas 
approximately 15% are related to changes in bioavailability (changes in gastrointestinal pH, 
presystemic clearance [mediated by CYP3A4 hepatic or intestinal]) or in P-glycoprotein 
activity). (Amariles et al., 2007b; Giraldo et al., 2010)  
For this chapter, the earlier published information (Amariles et al., 2007a, 2007b; Giraldo et 
al., 2010; Amariles, 2002.) have been complement with information achieved from both a 
structured and systematic review of publications on Pubmed/Medline and references cited 
in relevant articles, and in other electronic databases (SIETES, MEDSCAPE, and 
TRIPDATABASE), and supplemented by other primary and secondary information sources 
to identify DIs in HIV-infected patients. Thus, searched MeSH terms were drug interactions, 
antiretroviral agents (or drugs), drug food interactions, drug nutrient interactions, drug 
laboratory test interference, drug in special situations (age, diseases), drug herbal plant 
interactions, computerized drug interactions, decision clinical computer based, and clinical 
relevance, clinically relevant or significantly relevant.  
Finally, according with clinical relevance of the DIs, pairs of the identified DIs have been 
classified in four levels, according to rate probability and severity, (Amariles et al., 2007a, 
2007 b;  Giraldo et al., 2010) and then, the different drug pairs have been structured in a 
software designed to facilitate the identification, evaluation, and prediction of clinical 
relevant DIs. Current, 1,082 drug pairs of potential DIs have been identified, near to 80% of 
them due to pharmacokinetic mechanism (changes in plasma concentration), mainly 
associated to systemic enzyme inhibition. The scaling of these 1,082 drug pairs of recognized 
DIs, according to different dosage forms and strengths of identified drugs, generates a total 
of 6,087 pairs of DIs, in which, according their clinical relevance, 4,158 (68.3%) are clinical 
relevant (Levels 1 and 2) in HIV-infected patients receiving ARV therapy. Thus, the 
designed software meets the requirements defined for this type of program (Gaikwad et al., 
2007; Rodríguez et al., 2009) and most important it facilitates the assessment, prediction, and 
decision on clinical relevance of 4,158 ARV DIs, which are considered of clinical interest in 
patients with HIV/AIDS (levels 1 and 2). 
2. Drug interactions in HIV-infected patients receiving antiretroviral therapy 
2.1 Concept, type, and mechanism of drug interactions 
Concept of DI. In patients with HIV/AIDS a DI could be assumed as non-therapeutic and 
quantitative modification in the magnitude or duration of the drug effect (decrease the 
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efficacy or increase the toxicity) that may lead to therapeutic failure or adverse drug 
reactions associated to a previous or a concomitant use of another drug (drug-drug 
interactions), including herbal drug products (herbal-drug interactions), certain type of 
food (drug-food interactions) or due to a patient´s physio-pathological condition (drug-
disease interaction). (Amariles et al., 2007a) Additionally, changes on the results of certain 
laboratory tests that may produce some drugs (drug - laboratory tests interactions) 
(Maddox et al., 1980) or on the bioavailability of several nutrients (drug - nutrient 
interactions) (Chan, 2002; Santos & Boullata, 2005) may be considered as a DI. (Amariles, 
2002)  
Elsewhere, the increasing use of herbal products worldwide and the growth of the herbal 
product industry have led to rising the identification and characterization of clinically 
relevant DIs among several drugs with some of these products, for instance St. John's Wort 
(Hypericum Perforatum L.), which has been the characterization of another type of DI: 
herbal–drug drug interactions. (Markowitz & DeVane, 2001)   
Although from a pharmacological perspective, some DIs may lead to a required therapeutic 
effect, for instance “pharmacokinetic enhancement or ritonavir boosting,  strategy in which 
low doses of ritonavir -100 to 200 mg- (a cytochrome P4503A inhibitor) are used in 
combination with other protease inhibitors to increase antiretroviral drug exposure 
(Rathbun  & Rossi, 2002), from a risk perspective, the efforts should focus on evaluating, 
predicting, and solving DIs with high probability to produce effects that are undesirable and 
to arise toxicities or therapeutic failures, which are termed as clinically relevant drug 
interactions. (Amariles, 2002; Amariles et al., 2007a) 
Pharmacological mechanism of drug interactions. The previous or concomitant use of a 
drug, herbal drug product, or food (like a patient´s physio-pathological condition) may 
cause a non-therapeutic and quantitative modification in the magnitude or duration of 
the drug effect because such substance or situation causes an alteration that involve one or 
more of the three pharmacologic processes namely biopharmaceutics, pharmacokinetics, or 
pharmacodynamics.  
The biopharmaceutics is relating both to factors that influence the drug release from a 
drug product and the drug dissolution rate in the absorption site. Whereas, the 
pharmacokinetics is relating to drug absorption, distribution, metabolism, and excretion 
(ADME) (what the body does to the drug). As most drugs proceed through first order 
kinetics, and the process of ADME usually follows first order kinetics as well, the 
relationship between dose/time and drug plasma concentration for most drugs is linear. 
Thus, the biopharmaceutics and pharmacokinetics phases determine the drug plasma 
concentration. Similarly, since the relationship between plasma concentration and drug 
available on the site of action or biophase is linear, and the concentration on biophase is 
directly related to the intensity and duration of therapeutic response for most drugs as 
well, the relationship between drug plasma concentration and the magnitude of drug 
effect for most drugs is linear (figure 1).  
Pharmacodynamics phase (what the drug does to the body): the pharmacodynamics 
studies the mechanism of action (specific molecular drug-target interaction, usually as a 
result of binding to a receptor or an enzyme, through which a drug causes its 
pharmacological response or effect (pharmacological surrogate or clinical effect as result of 
drug- target interaction). 
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Fig. 1. Pharmacokinetics, plasmatic concentration (Cp), and pharmacologic effect. 
Based on the pharmacological mechanism that explains the non-therapeutic and quantitative 
modification in the magnitude or duration of the drug effect, the DI may be classified as:  
 Pharmacokinetic DI: The non-therapeutic and quantitative modification in the 
magnitude or duration of the drug effect is explained mainly by a change in the drug 
plasma concentration associate with substance or situation that causes the DI. The 
change in the drug plasma concentration may be attributed to a biopharmaceutic (drug 
release and dissolution) and/or pharmacokinetic (ADME) alteration. Thus, 
biopharmaceutic DIs are included in pharmacokinetic DIs (both biopharmaceutic and 
pharmacokinetic DIs are attributed to a change in the drug plasma concentration). 
 Pharmacodynamic DI: The non-therapeutic and quantitative modification in the 
magnitude or duration of the drug effect occurs without change in the drug plasma 
concentration. This type of DIs are mainly due to drugs or substances that have either 
similar (synergism) pharmacological effect or opposing (antagonistic) pharmacological 
effect or physio-pathological condition (drug-disease interactions) that contributes or 
facilities (synergism) the therapeutic or toxic effect of the drug, or that diminish or 
counteract its therapeutic effect (antagonism). In general, in one patient, the use of 
drugs those have a similar unsafe profile increases the likelihood and severity of 
adverse drug effects, for instance the use of drug-induced hepatic or renal toxicity.  
2.2 Proposal to evaluate and predict the clinical relevance of pharmacokinetic drug 
interactions in HIV-infected patients receiving antiretroviral therapy (Amariles et al., 
2007b) 
HAART or cART has improved survival of HIV-infected patients, but they currently have 
chronic co-morbidities which require pharmacologic interventions with several medications, 
increasing the risk of DIs. In clinical practice, it is known that DIs may lead important 
pharmacotherapy problems especially for illnesses which require using various 
medications. Therefore, clinically relevant DIs are frequent among HIV-infected patients 
who are receiving ARV therapy. (Miller et al., 2007) In this context, ARV drugs may lower 
the efficacy or enhance side effects or toxicity of several of these drugs, and similarly some 
of these drugs may cause therapeutic failure or increase the toxicity of ARV drugs. (Fletcher 
et al., 2000) 
DIs are especially important for drugs with narrow therapeutic indices and may either be 
pharmacodynamic or pharmacokinetic in nature. However, pharmacokinetic DIs may be more 
frequent complex to evaluate and to predict the effect among HIV-infected patients receiving 
ARV therapy. For instance, protease inhibitors (PIs), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), and the CCR5 antagonist maraviroc are metabolized through the CYP450 
system, mostly by CYP3A4. (DHHS, 2011) In addition, each of the NNRTIs and PIs induce 
and/or inhibit specific CYP450 enzymes and consequently are prone to cause pharmacokinetic 
DIs, (Pau & Boyd, 2010) mainly when they are concomitant used in patients with HIV and 
 
Pharmacokinetics
Dose/time 
Drug plasma
concentration (Cp)
Pharmacodynamics
Drug Effect Biophase 
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with others important co-morbidities, such as dyslipidaemia, hypertension, tuberculosis, and 
opiate dependence, in which is needing to use several drugs that may be both substrate and 
selected inducers or inhibitors of CYP3A4. (Josephson, 2010) 
In general, the clinical relevance of a pharmacodynamic DI can often be evaluated, predicted, 
and monitored easily, because the process is supported by knowledge of the drugs mechanism 
of action and pharmacological effects (therapeutic and adverse), complemented with the 
definition and monitoring of parameters related to the drug clinical effects (clinical effects and 
toxicity profile), if possible in a quantitative way. Whereas, the pharmacokinetic DIs 
(alterations in drug plasma concentration associated to changes in the release, dissolution, 
absorption, distribution, metabolism, or excretion of drug) are more complex and may not be 
as easily evaluated, predicted, and monitored as the pharmacodynamic DIs; thus, the process 
requires both knowledge of pharmacology, pharmacotherapy, and clinical expertise. Thus, it is 
important to present a development proposal, which have been adjusted with goal to evaluate 
and predict the clinical relevance of pharmacokinetic DIs in HIV-infected patients receiving 
ARV therapy. (Amariles et al., 2007b; Giraldo et al., 2010)  
2.2.1 Identifying and assessing if one of the medication that the patient is using (or 
that the patient will be use) is considered as a drug with narrow therapeutic indices 
The therapeutic index of a drug is the ratio of the dose that produces toxicity (drug plasma 
concentration that elicits the toxic effect in 50 percent of treated individuals -TD50-), and 
the dose that produces a clinically desired or effective response in a population of 
individuals (drug plasma concentration that elicits the therapeutic effect in 50 percent of 
the treated individuals -ED50-) as shown in equation 1 (Katzung, 2009) 
 
Both TD50 and ED50 are calculated from dose response curves, which represent the 
frequency with which each drug plasma concentration elicits the therapeutic effect or the 
toxic effect in the population (figure 2). 
 
 
Fig. 2. Dose-responsive curves and Therapeutic Index 
Equation 1. Index therapeutic = TD50/ED50 
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From a clinical perspective, drug therapeutic range corresponds at drug plasma concentrations 
associate to likelihood of achieving, in the most patients, the maximum therapeutic effect with 
the minimum toxic effect. The probability that a pharmacotherapy process will be effective 
and safe increases if both the maximum drug plasma concentration and the minimum drug 
plasma concentration of the steady state associate to a specific dosing schedule in a patient 
are included within the therapeutic range (population) or therapeutic index (individual) of 
the drug (minimum effective level and minimum toxic level, which are theoretical). If the 
concentrations achieved at steady state are outside of the therapeutic range or index 
(excluded), it is increases the probability of drug failure or ineffective (if the concentration is 
lesser than the minimum effective level) or of adverse or toxic effects (if the concentration is 
higher than the minimum toxic level). Therefore, drug therapy should obtain that the achieved 
drug plasma concentrations at steady state are included within the therapeutic range or index 
(theoretical) is a specific patient, as shown in figure 3. 
 
 
Fig. 3. Relationship between drug plasma concentrations achieved in steady state and the 
theoretical therapeutic window (therapeutic index or therapeutic margin) 
The probability that a pharmacokinetic DI causes that the drug achieved drug plasma 
concentrations at steady state are outside of the therapeutic range or index is inversely 
proportional to the difference between minimum effective level and minimum toxic level 
that are defined in the therapeutic index or range of the drug. The probability is higher 
(increased) for drugs with small difference between the minimum effective concentrations 
and the minimum toxic concentrations (drugs with a narrow therapeutic range or index). 
It could be practice to consider a narrow therapeutic range or index drug if the drug: (FDA, 
2005) (1) Require pharmacokinetics (therapeutic drug concentration) or pharmacodynamic 
(measuring clinical effects) monitoring, thus the effective and safe use of the drug require 
careful dosage titration and patient monitoring; (2) have less than a 2-fold difference in 
median lethal dose (LD50) and median effective dose (ED50) values; or (3) have less than a 2-
fold difference in the minimum toxic plasma concentrations and the minimum effective 
plasma concentrations 
From a clinical practical perspective, there are lists of narrow therapeutic index drugs, 
including their minimum effective concentrations and the minimum toxic concentrations, 
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which include drug as digoxin, lithium, vancomycin, aminoglycosides, and anticonvulsants. 
Although it is knowing that some drugs has narrow therapeutic index, for instance oral 
anticoagulants and insulin, they may not be included in this kind of lists, mainly due to: (1) 
Absence of population data of minimum toxic concentrations and minimum effective 
concentrations; (2) presence of a large interindividual pharmacodynamic variability (in 
some patient a similar drug plasma concentration may cause different magnitude or 
duration of the clinical effects); and (3) there are not a reasonable relationship between drug 
plasma concentrations and clinical effects. For that reason, although data for dose-response 
curves is obtained from several individuals, the therapeutic index is assumed more as an 
individual perspective whereas therapeutic range is assumed more as a population 
perspective. 
 
ARV drugs as Narrow Therapeutic or Range Index Drugs. Due to their pharmacological 
and clinical features, ARV drugs may be considered as narrow therapeutic or range index 
drugs. (FDA, 2005) For instance, although there are some controversies due to broad intra- 
and inter-individual pharmacokinetic variability of ARV drugs, (Nettles et al., 2006) PIs and 
NNRTIs have defined drug plasma concentrations related to maximum efficacy and safety 
(therapeutic range) and, therefore ARV drugs are susceptible to therapeutic drug 
monitoring (assessing and monitoring drug concentration) (Justesen, 2006; Wertheimer et 
al., 2006), as shown in table 1. As consequence, it is possible to establish, that patients that 
are receiving PI/NNRT have a high susceptibility to present clinically relevant DIs.  
Additionally, some medications used in HIV-infected patients for treatment or prevention of 
some chronic co-morbidities and opportunistic infections may be considered as narrow 
therapeutic range or index drugs, for instance rifampin, rifabutin and other antibiotics, 
anticonvulsants, statins, antidepressants, antihypertensives, and opioids (DHHS, 2011). 
2.2.2 Identifying and predicting consequences of drug interaction on the 
pharmacokinetics, plasma concentrations, and affected drug clinical effects (step 
more complex) 
The consequences of a pharmacokinetic DI on the main pharmacokinetic process, on the 
drug plasma concentrations, and thus on the affected drug clinical effects, depends among 
other aspects, of: (1) the magnitude that the respective pharmacokinetic process affects  
In drug therapy process using drugs with a narrow therapeutic range or index, 
pharmacokinetic DIs may cause an increase in blood/serum concentrations and thus could 
lead to drug toxic effects, or may cause a decrease in blood/serum concentrations and thus 
could lead to drug failure or ineffectiveness. Therefore, in the process of evaluate and 
predict the clinical relevance of a DI, the first stage is to establish whether any drugs that 
patient is using (or that will use) is considered as a narrow therapeutic range or index 
drug. In general, if the drugs used have a broad therapeutic index or margin, the probability 
of a pharmacokinetic DI makes that the drug be unsafe or ineffective is low, because the 
probability of a change leads to achieved drug plasma concentrations are excluded at the 
therapeutic range or index (below of the minimum effective concentrations or above of the 
minimum toxic concentrations) is minimum. In general, if pharmacokinetic DIs (as well as 
pharmacodynamic DIs) involves drug products that are not considered as narrow 
therapeutic range or index drugs they will be clinical irrelevant; therefore in these cases 
the evaluating and predicting of DI may not be needed. 
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Drug    Therapeutic range or index (ng/mL) 
Saquinavir   250 – 600 
Ritonavir (solo)   150 - 2.100 
Indinavir   100 - 1.000 
Nelfinavir   800 - 3.000 
Amprenavir   400 - 2.200 
Lopinavir/ritonavir  1.000 - 9.000 
Atazanavir   150 - 1.000 
Tipranavir   6.500 - 50.000 
Nevirapine Cmin   3.500 
Efavirenz   1.000 - 4.000 
Delavirdine   Limited information 
aAssessment as its active metabolite (m8). Cmin: minimum concentration 
Table 1. Drug plasma concentrations related to effective minimum level and toxic minimum 
level that defined the therapeutic index or range of ARV drugs. (Justesen, 2006; Nettles et al., 
2006; Wertheimer et al., 2006) 
achieved drug plasma concentrations with the dosing-schedule used in the patient; and (2) 
the magnitude of change that the DI causes on altered pharmacokinetic process. These two 
aspects determine the influence of a DI both on the magnitude of change on drug plasma 
concentrations and on the probability of achieved drug plasma concentrations at steady 
state are excluded from the therapeutic range or index.  Relate to this issue, the average 
steady-state concentration (Cpss) is an excellent estimator of achieved drug plasma 
concentrations, which is determined by the ratio between the drug delivery rate (input rate, 
which depends directly on the dose –D-, and the bioavailability –F-, and inversely on the 
dosing interval -τ-), and the clearance rate –CL- (output rate), as shown in equation 2.  
 
Bioavailability (F). Although, bioavailability of drug is classically defined as the rate and 
extent to which the active ingredient (drug substance) is absorbed from the dosage form 
(upon oral administration), from a clinical perspective, this pharmacokinetic parameter 
may be assumed as the amount of active ingredient (drug substance) from the dosage 
form (drug product, upon oral administration) that reaches the systemic circulation 
unchanged. Therefore, the bioavailability of drug is influenced by: (1) the disintegration 
of the dosage form, the release of drug from a drug product, and the dissolution of drug 
in the absorption site; (2) the presystemic metabolism both in the gut lumen (extra-
hepatic) and in the liver by CYP450, especially CYP3A4; and (3) the contribution of 
intestinal transporters, which may decrease the bioavailability, by efflux effect of 
intestinal P-glycoprotein (P-gp) in drug absorbed from apical to basolateral), or may 
increase the bioavailability, by effect of the anionic organic polypeptide (TAOP), 
especially the type B. (Ho & Kim, 2005)  
Systemic or total clearance (CL) is defined as the volume of plasma in the vascular 
compartment cleared of drug per unit of time [volume/time], mainly by hepatic metabolism 
Equation 2. Cpss = ۲ ܠ ۴ૌ ܠ ۱ۺ  
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(hepatic clearance) or by renal excretion (renal clearance) but also by other ways, such as 
biliary excretion. CL is a measure of the efficiency of human organism to remove 
irreversibly a drug from the systemic circulation or bloodstream by all routes of elimination, 
mainly by biotransformation (or drug metabolism) and excretion.  
Drugs are metabolized (changed) usually by enzymes found mainly in the liver but also in 
small intestine, lung, kidney, and skin to a metabolites by process known as drug 
metabolism or biotransformation. Biotransformation often changes no-polar or lipophilic 
drugs into metabolites more polar or hydrophilic, which tend to be excreted in the urine 
(renal excretion) or in the stool (biliary excretion) as glucuronate, sulphate or acetate 
conjugates. While, polar or hydrophilic drugs may be excreted without drug metabolism 
through renal excretion.  
A renal pharmacokinetic DI may be clinically relevant if: (1) there is a competitive inhibition 
of tubular secretion of the drug and (2) the renal clearance contributes more than 30% and 
drug systemic clearance. (Bonate et al., 1998; Launay et al., 2006) Additionally, certain 
drugs, for instance ritonavir may inhibit the renal secretion of certain drugs, which may be 
critical for drugs that are mainly eliminated by this via. For example, when digoxin is used 
concomitant with ritonavir, the PI may lead to an increase in the levels and pharmacological 
effects of digoxin. (Ding et al., 2004) 
Concepts provide above, particularly the equation 2, lead to understand why clinically 
relevant pharmacokinetic DIs are mainly explained by changes in systemic clearance and 
bioavailability. Thus, almost 80% of pharmacokinetic DIs are related to changes in systemic 
clearance, mainly associated to the systemic inhibition or induction of the metabolic activity 
of the CYP450 isoenzymes, and approximately 15% related to changes in bioavailability 
(changes in gastrointestinal pH, presystemic clearance [by hepatic or intestinal CYP3A4 
isoenzyme]) or by in P-gp activity). (Amariles et al., 2007b; Giraldo et al., 2010)  
 
Because a near to 80% of clinically relevant pharmacokinetic DIs are related to hepatic 
metabolism, both systemic and presystemic, during the process of developing new drugs it 
is important to characterize and to predict DIs related to hepatic metabolism. With this goal, 
both cell cultures are used to establishing the ability of the new drug to modify the activity 
of major CYP450 isoenzymes, and the assessment of the susceptibility of the drug 
metabolism to be affected by drugs recognized as enzyme inhibitors and inducers. (Tucker, 
2001; Obach et al., 2005, 2006) 
The major route of elimination of PIs and NNRTIs is by hepatic metabolism and thus the 
pharmacokinetic DIs may be clinical relevant. Not at all, for nucleoside or nucleotide 
The process of evaluating and predicting of the clinical relevance of a pharmacokinetic 
DI continues with the identification if the main route of drug elimination is hepatic o 
renal, and thus if the drug is remove irreversibly from the systemic circulation or 
bloodstream by excretion renal or by hepatic metabolism. Generally, if the drug is 
eliminating by hepatic metabolism, the probability that a pharmacokinetic DI will be 
clinical relevant is elevated. In these cases, subsequent to identify whether the systemic 
elimination of any drugs that patient is using (or drugs that patient will use) occurs 
primarily by hepatic metabolism, the process must continue with the evaluation of the 
effect that may cause one possible hepatic metabolism inhibition or induction on 
drug plasma concentrations. 
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analogue reverse transcriptase inhibitors (NRTIs), due to they are eliminated primarily by 
renal excretion, clinically relevant pharmacokinetic DIs are less frequent. However, among 
NRTIs, abacavir is metabolized by alcohol dehydrogenase and zidovudine by gucoronil-
transferase, which may cause that these two drugs to have interactions associated to changes 
in the activity of the respective enzymes. Additionally, there is evidence that tenofovir may 
modify the atazanavir metabolism and thus drug plasma concentrations and clinical effects 
of this PI; similarly, atazanavir and lopinavir/ritonavir may alter the drug plasma 
concentrations and clinical effects of tenofovir (see below). In addition, the systemic 
elimination of some drugs, considered as narrow therapeutic index or margin drugs, and 
commonly used in patients with HIV/AIDS (such as rifamycins, anticonvulsants, statins, 
and antidepressants) occurs by hepatic metabolism and, therefore, clinically relevant 
pharmacokinetic DIs are likely to arise. 
2.2.2.1 Evaluation of the effect that may cause one possible hepatic metabolism inhibition 
or induction on the plasma concentrations of the potentially affected drug  
The process of evaluation of a DI associated to hepatic metabolism needs: (1) identify the 
CYP450 enzyme which is responsible for the biotransformation of the drug whose 
metabolism can be altered, and (2) identifying agents that alter (induce or inhibit) the 
metabolic capacity of the CYP450 enzyme. The proper observance of this stage implies 
following three steps. 
a. Identification of the CYP450 enzyme which is responsible for the biotransformation of 
the drug that may be altered. A detailed and updated list of major CYP450 isoenzymes, 
together with their most common substrates, inhibitors, and inducers can be found on 
the following web sites: 
 http://medicine.iupui.edu/clinpharm/DDIs/ and  
 http://medicine.iupui.edu/clinpharm/DDIs/ClinicalTable.asp  
In the case of PIs and NNRTIs, their systemic metabolism occurs primarily by CYP3A4. 
Additionally, there are other drugs commonly administered to HIV/AIDS patients which 
are metabolized by CYP3 or CYP2 families. 
b. Identifying drugs that may modify (inducing or inhibiting) the metabolic capacity of 
CYP2 and CYP3 families. For instance, rifampin, rifabutin, carbamazepine, 
phenobarbital, phenytoin, and Saint-John’s-wort may induce the activity of CYP2 and 
CYP3 families, whereas azole antifungals, macrolides, calcium antagonists, 
immunosuppressants, and grapefruit juice may inhibit CYP3 family. Most the drugs 
ARV used in the treatment of HIV are metabolized by the CYP450 enzymes and they 
have the capacity to modify the activity of CYP3 family and, to a lesser extent, the 
activity of CYP2 family. Among the NNRTIs, efavirenz and nevirapine mainly induce 
CYP3A4 and CYP2B6, while delavirdine is primarily an enzymatic inhibitor of the 
CYP3A4, and etravirine inhibits CYP2C9 and CYP2C19 while inducing CYP3A4. 
However, efavirenz may inhibit the activity of CYP3A4, CYP2C9, and CYP2C19 
isoenzymes. In vitro studies show most of the PIs are inhibitors of activity of CYP3A4 
isoenzyme (atazanavir, darunavir/ritonavir, lopinavir/ritonavir, saquinavir, 
tipranavir/ritonavir) or strong CYP3A4 inhibitors (ritonavir, indinavir, nelfinavir). 
Some PIs both inhibit and induce CYP3A4 (amprenavir, fosamprenavir). Ritonavir also 
inhibits CYP2D6. The NRTIs, the fusion inhibitor enfuvirtide, and the integrase 
inhibitor raltegravir are not metabolized by the CYP450 system.  
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c. Determining if the pharmacokinetic DI related to hepatic metabolism might be either 
one-way or two-way direction (bidirectional) and if it might affect the levels and effects 
of the two drugs involved; situation that is likely to occur, because the need to use 
simultaneously either inhibitor drugs (e.g., macrolides and antifungal azoles) or inducer 
drugs (for instance rifampicin and carbamazepine) together with PIs and/or NNRTIs is 
common. 
2.2.2.2 Evaluation of changes in the bioavailability of drugs orally administered 
Changes in presystemic metabolism (due to inhibition or induction of extra-hepatic or 
hepatic CYP3A subfamily), in the activity of P-gp, or in the gastrointestinal pH may affect 
both the amount absorbed and the effects of some ARV drugs. In turn, antiretroviral drugs, 
particularly PIs, may modify the bioavailability and effects of some drugs, mainly through 
inhibition of presystemic metabolism and, to a lesser extent, of the activity of P-gp. 
Didanosine, especially in its dosage form as buffer solution, can change gastrointestinal pH 
and the amount absorbed by some drugs. 
For drugs with kinetics elimination of first order or linear (most drugs used at therapeutic 
doses, phenytoin is one important exception), as it may be deduced from the equation 2, the 
increase or decreases of average steady-state concentration (Cpss) is inversely related to the 
decrease or increase of CL (Cpss1/CL). Generally, for narrow range or index drugs, a 
pharmacokinetic DI may be clinically relevant, if the DI causes a change in the achieved 
Cpss of +/-20% (FDA, 1999). As Cpss  1/CL, a decrease (associate to a reduction of hepatic 
metabolism) in the CL of 10%, 15%, 20%, 30%, 50%, and 75% may produce an increase in the 
Cpss of 11%, 18%, 25%, 43%, 100%, and 400%, respectively. The expected increasing of Cpss 
is calculated from the ratio of 100 divided by 100 less the percentage that CL is decreasing 
[100/ (100 less % of decrease of CL)]. Thus, if CL decreases in 10%, the increase of 11% is 
obtained from the ratio of 100 divided by 100 less 10 (100/90), which result is 111% and it is 
showing that Cpss increases in 11%. Similarly, 43% is obtained from the ratio of 100 divided 
by 100 less 30 (100/70) which result is 143% and it is showing that Cpss increases in 43%; 
and so similarly for other values. (Amariles, 2002) In the situations of increases of hepatic 
metabolism (induction enzymatic), it is requiring a minimal increase of 25% in CL, which 
may be caused a decrease of 20% in the achieved Cpss.  
The drug plasma concentration before of the pharmacokinetic DI is another factor that 
contributes significantly to the magnitude of change in the clinical effect. For example, if 
diltiazem may decreased CL of quinidine (therapeutic range: 1-4 g/mL) in 35% (Laganiere 
et al., 1996), thus it may cause an increase of 54% in the achieved Cpss of quinidine. Thus, if 
the quinidine Cpss on time interaction was of 2.5 g/mL, it would increase to 3.85 g/mL, 
whereas if the quinidine Cpss was of 3.5 g mL, it would increase to 5.39 g/mL. As 
In clinical practice, inhibition of hepatic CYP enzymes or metabolic inhibition is one of 
the most common DI mechanisms and it is usually reversible and competitive. Most 
pharmacokinetic DIs occur when a drug increases or decreases metabolism of other 
drugs in the liver (CYP enzymes or glucuronidation). When a drug or substance causes a 
decrease in the systemic hepatic metabolism and clearance of a drug, this substance 
generates an increase in plasma concentrations and may lead to emerge of adverse drug 
events or toxicities. Thus, the process of evaluating and predicting the effects of this kind 
of DI needs to identify the drugs that are strong or moderate inhibitors of activity of 
different CYP450 isozymes known also as "enzyme inhibitors for excellence". 
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consequence, the probability of toxicity at 5.39 g/mL (outside the therapeutic range) is 
higher than at 3.85 g/mL (within the therapeutic range). (Amariles, 2002)  
2.3 Determining and predicting of the clinical relevance level (Amariles et al., 2007a)  
A relevance analysis of a DI should result in determining and predicting the clinical 
relevance level based on the gravity and probability of occurrence of the DI. The probability 
of the DI is set to 3 categories: defined, probable, and possible, whereas the gravity of the 
DI is grouped into 3 categories: grave, moderate, and mild. Based on the possible 
combinations of gravity and probability of occurrence, interactions can be grouped into 4 
categories: 
 Level 1 (Very high risk) resulting from the combination of: defined and grave or 
probable and grave. The simultaneous use of drugs is considered absolutely 
contraindicated.  
 Level 2 (High Risk) resulting from the combinations of: possible and severe, defined 
and moderate, or probable and moderate. The simultaneous use of drugs is considered 
contraindicated: combined administration should be avoided or, if it is need, the dosage 
regimen of affected drug may be adjusted and to assess signs and symptoms associated 
to treatment effectiveness and safety, ideally in a quantitative form.  
 Level 3 (Medium risk) resulting from the combination of: possible and moderate, 
defined and mild, or probable and mild. The simultaneous use of drugs requires 
assessing signs and symptoms associated to treatment effectiveness and safety, ideally 
in a quantitative form. 
 Level 4 (Low risk) resulting from the combination can be mild. The interaction is of 
little clinical relevance. 
 
3. Clinical relevance of pharmacokinetic drug interactions in HIV-infected 
patients receiving antiretroviral therapy  
In this apart, using the previously described proposal, the evaluating and predicting the 
clinical relevance of pharmacokinetic DIs in HIV-infected patients receiving antiretroviral 
therapy is presented. (Amariles et al., 2007b; Giraldo et al., 2010) 
3.1 Drug interactions due to enzyme inhibition mediated by PIs or NNRTIs 
The process of evaluating and predicting the effects of this kind of DI needs to identify the 
drugs that are strong or moderate inhibitors of activity of different CYP450 isozymes known 
also as "enzyme inhibitors for excellence".  
In general, PIs (ritonavir > indinavir ≈  nelfinavir ≈ lopinavir ≈ atazanavir ≈ amprenavir –
fosamprenavir- ≈ darunavir ≈ tipranavir >  saquinavir) (Boffito et al., 2006), delavirdine (Tran et 
al., 2001) and, in some cases, efavirenz, (DeSilva et al., 2001) can inhibit the systemic metabolism  
From a clinical perspective, predicting of the clinical relevance of a DI should be 
improvement by clinical experience and knowledge obtained from situations similar; 
thus, the clinical interpretation of the information, including drug history and the 
patient's clinical condition is critical. Therefore, the presence of concomitant diseases and 
the need to use other drugs, the condition of renal and hepatic function, as the age and 
nutritional condition are factors that influence the clinical relevance of a determine DI. 
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Drug group or drugs 
affected
Clinical 
relevance: level
Comments and suggestions 
Antiarrhythmic drugs a 
 Flecainide 
 Disopyramide 
 Amiodarone 
2: high risk Increased likelihood of security problems, 
especially gastrointestinal, muscular and 
cardiac conduction problems. 
Recommendation: dose adjustment and 
monitoring plasma levels
Antihistamines anti-H1 a
 Terfenadine 2: high risk 
More likelihood of increasing QTc interval on 
the electrocardiogram and occurrence of 
cardiac arrhythmias, as well as dizziness 
Recommendation: avoid co-administration 
 Astemizole  1: very high risk
Ergot alkaloids a 
 Ergotamine 
 Dihydroergotamine 
 Ergonovine 
 Methylergonovine
2: high risk Increased likelihood of ergotism: 
hypertension, nervousness, hallucinations, 
seizures, gastrointestinal, and muscle 
disorders. Recommendation: dose adjustment 
and monitoring
Benzodiazepines a
 Midazolam 
 Triazolam 
 Alprazolam 
2: high risk Increased likelihood of respiratory depression, 
sedation and muscle weakness. Oxazepam, 
lorazepam or temazepam are an alternative, 
because they are eliminated by conjugation 
with glucuronic acid and are hardly affected by 
the simultaneous use of PIs. Recommendation: 
dose adjustment and monitoring
Statins a (Aberg et al., 
2006; Bays, 2006; Benesic 
et al., 2004; Cooper et al., 
2003; Fichtenbaum et al., 
2002; Fichtenbaum & 
Gerber, 2002; Hare et al., 
2002; Jacobson, 2004; Sax, 
2006; Sudano et al., 2006). 
 Lovastatin 
 Simvastatin 
 Atorvastatin
 
 
 
 
2: high risk  
 
Increased risk of myopathy, rhabdomyolysis, 
and even death. Avoid the use of lovastatin or 
simvastatin in patients using ritonavir, 
atazanavir and saquinavir. Recommendation: 
to use the lowest possible dose (for 
atorvastatin) and to monitor signs and 
symptoms of muscle toxicity, or use statins 
involving  lower risk for this type of 
interaction, such as pravastatin, fluvastatin, or 
rosuvastatin 
 Rosuvastatin 
 Fluvastatin 
 Pravastatin 
3: medium risk
Calcium antagonists no-
dihydro-pyridines a 
 Verapamil 
 Diltiazem 
2: high risk Increased risk of hypotension and reduced 
cardiac conduction. It is recommended to 
reduce the dose of these two drugs by half 
Phosphodiesterase type V a
 Sildenafil 
 Tadalafil 
 Vardenafil 
2: high risk 
 
Increased risk of hypotension, priapism, 
headache, and visual disturbances. Doses 
should be adjusted: sildenafil to 25 mg/48 
hours, tadalafil to 10 mg/72 hours, and 
vardenafil to 2.5 mg/72 hours
Cisapride a 2: high risk Increased likelihood of increasing the QTc 
interval on the electrocardiogram and cardiac 
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arrhythmias, as well as gastrointestinal 
disturbances and dizziness. Recommendation: 
Dose adjustment and monitoring
Pimozide a 2: high risk 
 
Increased likelihood of involuntary 
movements (tics), agitation, confusion, 
behavioral disturbances, and tachycardia. 
Recommendation: Dose adjustment and 
monitoring
Warfarina 
(acenocumarol) 
2: high risk 
 
The risk of bleeding may increase, when this 
combination is used. Recommendation: dose 
adjustment and monitoring international 
normalized ratio (INR)
Fluticasone a (Arrington-
Sanders et al., 2006)  
2: high risk 
 
PIs, especially ritonavir alone or with other 
PIs, tipranavir, and indinavir may increase 
fluticasone levels, and even lead to the 
development of Cushing syndrome, especially 
with the use of ritonavir in children. 
Recommendation: Dose adjustment and 
monitoring
Opioid analgesics 
(Armstrong & Cozza, 
2003a, 2003b) Oxycodone 
 Oxycodone 
 Buprenorphine 
 
 
 
2: high risk  
 
 
Protease inhibitors may inhibit CYP2D6 and 
CYP3A4 and thus the metabolism of 
oxycodone and buprenorphine, increasing 
their plasma concentrations as well as the 
likelihood of toxic effects (sedation and 
respiratory depression) 
Dihydrocodeine, hydrocodone, and codeine are 
pro-drugs and require activation by CYP2D6 or 
glucuronyltransferase. Therefore, protease 
inhibitors can inhibit the metabolism and the 
formation of the active compound and, 
therefore, the pharmacological effect of these 
drugs. However, codeine is considered a 
suitable option for pain control in HIV-infected 
patients receiving antiretroviral therapy 
 Dihydrocodeine 
 Hydrocodone
2: high risk 
 Codeine   3: medium risk
Tricyclic and tetracyclic 
antidepressants (Cvetkovic 
et al., 2003; de Maat et al., 
2003; Oldfield & Plosker, 
2006; Von et al., 1998)  
 Amitriptyline 
 Desipramine 
 Nortriptyline 
 Mirtazapine 
 Trazodone 
 Nefazodone 
2: high risk Ritonavir alone or with another PI can inhibit 
CYP2D6, and thus, the metabolism of these 
drugs, which can generate toxicity problems, 
particularly decreased conduction and cardiac 
arrest, as well as increased anticholinergic 
effects (constipation, dry mouth, urinary 
retention) and cardiac abnormalities. It is 
recommended to reduce the dose by  half (or 
use the lowest dose possible) of these two 
drugs, with adjustments based on their 
effectiveness and safety
Antidepressants reuptake 
inhibitors  (SSRI) (Aberg, 
2: high risk Ritonavir alone or with another PI can inhibit 
CYP2D6, and thus, the metabolism of these 
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2008; Acosta, 2002; 
Caballero & Nahata 2005; 
Currier et al., 2004; de 
Maat et al., 2003; Isbister 
& Buckley, 2005; Tseng  & 
Foisy, 1999)  
 Fluoxetine 
 Fluvoxamine 
 Venlafaxine 
 Paroxetine 
 Sertraline 
drugs, which can lead to increased levels and 
toxicity of SSRIs (serotonin syndrome). It is 
recommended using half or the lowest dose 
possible of either drug, setting the dose in 
terms of their effectiveness and safety. 
Citalopram and possibly escitalopram and 
sertraline, due to their low metabolism and 
effect on CYP activity, are considered the most 
suitable option in HIV-infected patients 
receiving antiretroviral therapy 
Integrase inhibitors 
Maraviroc (Aberg, 2008)  
2: high risk PIs increase plasma levels of maraviroc. 
Recommendation: reduce the dose of 
maraviroc up to 50% and monitoring 
With specific PIs
Drug group or 
drugs affected 
PIs Clinical 
relevance: 
level 
Comments and suggestions 
Simvastatin 
(Schmidt et al., 
2007)  
Atazanavir 2: high risk Inhibition of CYP3A4 by ATV, the 
increase in the levels and toxicity 
simvastatin increases the risk of 
rhabdomyolysis and acute renal 
failure. Recommendation: dose 
adjustment and monitoring 
 Efavirenz 
 Paclitaxel 
 Losartan 
 Diclofenac 
 Phenytoin 
 Amitriptyline 
 Omeprazole 
 Fluoxetine 
 Warfarin 
 Iibuprofen 
 Glibenclamide 
(Dixit et al, 
2007) 
Ritonavir, 
nelfinavir 
3: medium 
risk 
Increased metabolism of drugs 
metabolized by CYP2B6, CYP2C8, 
CYP2C9, CYP2C19. Recommendation: 
monitoring 
Tenofovir (Tong 
et al., 2007)  
ATV, PV, DRV, 
SQV, FPV 
2: high risk The coadministration of TDF with 
ATV, LPV, DRV and SQV increased 
Cp of tenofovir, while decreases Cp of 
FPV. Recommendation: dose 
adjustment and monitoring 
Warfarin (Hughes 
et al., 2007) 
LPV/r 3: medium 
risk 
LPV/r may increase the metabolism of 
S enantiomer of warfarin by 
stimulation of CYP2C9, as well as the 
R enantiomer by stimulation of 
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CYP1A2. Recommendation: INR 
monitoring
Minociline 
(DiCenzo et al., 
2008) 
ATV 3: medium 
risk 
Decreased levels and effect of ATV, 
possibly due to enterohepatic cycle 
interference associated to alterations of 
the intestinal bacterial flora. 
Recommendation: monitoring  
Etravirine (Aberg, 
2008)  
ATV/r 1: very high 
risk
ATV Cp is decreased by 38%. Avoid 
co-administration. 
Tipranavir 1: very high 
risk 
Etravirine Cp was reduced by 75%. 
Avoid co-administration 
FPV/r 1: very high 
risk
FPV Cp is decreased by 77%. Avoid 
co-administration
LPV/r 2: high risk Etravirine Cp may be increased by 
85%. Recommendation: dose 
adjustment and monitoring 
DRV/r 3: medium 
risk
Etravirine Cp may be decreased by 
50%. Recommendation: monitoring  
NFV 2: high risk Concomitant use increase plasma 
concentrations of nelfinavir, due to the 
inhibitory effect of etravirine on 
CYP3A4. Recommendation: dose 
adjustment and monitoring (Schöller 
et al., 2006a; Sekar et al., 2006a) 
Raltegravir 
(Aberg, 2008)  
Tipranavir
 
2: high risk Plasma concentrations of raltegravir 
are reduced when it is used with 
tipranavir. Recommendation: dose 
adjustment and monitoring 
ATV 2: high risk Plasma concentrations of raltegravir 
are increased when it is used with 
ATV. Recommendation: dose 
adjustment and monitoring 
Darunavir  SQV(Sekar et 
al., 2006a) 
2: high risk
 
Plasma concentrations and effects of 
these PIs may be increased, due to the 
inhibitory effect of darunavir. 
Recommendation: dose adjustment and 
monitoring 
LPV (Sekar et 
al., 2006b)
2: high risk
IDV 3: medium 
risk 
NVP 3: medium 
risk
 Pravastatin 
 Sildenafil 
 Vardenafil 
 Tadalafil 
DRV (Sekar et 
al., 2008) 
2: high risk
 
Plasma concentrations and effects of 
these medications may be increased, 
due to the inhibitory effect of 
darunavir. Recommendation: dose 
adjustment and/or monitoring  
 Budesonide 
 Quinine 
RTV and LPV/r
(Daveluy et al, 
2: high risk
 
Plasma concentrations and effects of 
these medications may be increased, 
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 Docetaxel 
 Fluticasone 
 Oxycodone 
 Alprazolam 
 Sirolimus 
 Quetiapine 
2009; Gray et 
al., 2010; 
Gruber & 
McCance-Katz, 
2010)  
due to the inhibitory effect of 
ritonavir. Recommendation: dose 
adjustment and monitoring 
Cannabinoids 
(Abrams et al., 
2003) 
IDV
NFV 
RTV 
2: high risk
 
Plasma concentrations and effects of 
cannabinoids and marihuana derivates 
may be increased, due to the 
inhibitory effect of PIs. 
Recommendation: dose adjustment 
and monitoring, or avoid use of 
cannabinoids 
Methadone  LPV/r 
(McCance-Katz 
et al., 2003) 
2: high risk Plasma concentrations and effects of 
methadone may be increased, due to 
inhibitory effect of PIs on CYP3A4. 
Recommendation: dose adjustment of 
methadone and/or monitoring 
adverse effects of methadone 
NFV 
(McCance-Katz 
et al., 2004)
2: high risk
ATV (Friedland 
et al, 2005)  
3: medium 
risk 
FPV (Cao et al., 
2008)
3: medium 
risk
IDV 3: medium 
risk 
Quetiapine 
(Hantson et al., 
2010)  
ATV 2: high risk
 
Plasma concentrations and effects of 
quetiapine are increased, due to 
inhibitory effect of atazanavir. 
Recommendation: dose adjustment of 
quetiapine and monitoring 
Antineoplasics 
(Levêque et al., 
2009; Makinson et 
al., 2010) 
 Irinotecan 
 Vinblastine 
 Vincristine  
LPV/r 3: medium 
risk 
Plasma concentrations and effects of 
these antineoplastics may be 
increased, due to inhibitory effect of 
LPV/r on CYP3A5.  
Recommendation: monitoring 
a Protease inhibitors (ritonavir → indinavir ≈ nelfinavir ≈ atazanavir≈ amprenavir- fosamprenavir- ≈ 
tipranavir → saquinavir), mainly through inhibition of CYP3A4, may decrease the metabolism of these 
drugs, which can cause increased plasma concentrations and toxicity. 
Table 2. General interactions due to enzyme inhibition by protease inhibitors (Boffito et al., 
2006; Busti et al., 2004; DeSilva et al., 2001; DHHS, 2011; Krikorian & Rudorf, 2005; Piscitelli  
& Gallicano, 2001; Kashuba, 2005a; Robertson et al., 2005a; Tran et al., 2001; Winston & 
Boffito, 2005; Wire et al., 2006)  
of several drugs, increase their plasma levels, and may cause adverse drug reactions, which 
could cause grave health problems in patients. Thus, according to their clinical relevance, most 
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could be classified in level 1 or 2. Table 2 lists the interactions mediated by enzyme inhibition 
caused by PIs. Table 3 contains the interactions mediated by delavirdine and efavirenz.  
 
Drug group or drugs 
affected 
Clinical relevance: level Comments and suggestions 
Delavirdine Efavirenz 
Anti-H1 antihistamines a
 Terfenadine 2: high risk 2: high risk 
More likely to increase QTc interval 
on the electrocardiogram and 
cardiac arrhythmias, as well as 
dizziness. Recommendation: avoid 
co-administration
 Astemizole 1: very high 
risk 
1: very high 
risk 
Ergot alkaloids a 
 Ergotamine 
 Dihydroergotamine 
 Ergonovine 
 Methylergonovine 
2: high risk 2: high risk Increased likelihood of ergotism: 
hypertension, nervousness, 
hallucinations, seizures, 
gastrointestinal and muscle 
disorders. Recommendation: dose 
adjustment and monitoring 
Benzodiazepines a
 Midazolam 
 Triazolam 
 Alprazolam 
2: high risk  2: high risk Increased likelihood of respiratory 
depression, sedation and muscle 
weakness. Oxazepam, lorazepam 
or temazepam are an alternative, 
because they are eliminated by 
conjugation with glucuronic acid 
and are hardly affected by  the 
simultaneous use of PI 
Statins (Bays, 2006; 
Cooper et al., 2003; 
Fichtenbaum & Gerber, 
2002; Jacobson, 2004; Sax, 
2006; Sudano et al., 2006.) 
 Lovastatin 
 Simvastatin 
 Atorvastatin
 
 
 
 
 
2: high risk 
Efavirenz 
acts as an 
inducer of 
statins 
metabolism 
(see 
interactions 
induction) 
Increased risk of myopathy, 
rhabdomyolysis, and even death. It 
should be avoided in patients using 
delavirdine (see text: 3.1.1 statins 
with PIs or delavirdine) 
 Rosuvastatin 
 Fluvastatin 
 Pravastatin 
3: medium 
risk 
Calcium antagonists not 
dihydro-pyridine a 
 Verapamil 
 
2: high risk 
Information 
not 
available 
Especially with delavirdine, it 
increases the risk of hypotension 
and reduced cardiac conduction. 
Consider to use the half dosing 
schedule of these two drugs 
 Diltiazem 3: medium 
risk 
Phosphodiesterase Type V 
inhibitors a 
 Sildenafil 
 Tadalafil 
 Vardenafil 
2: high risk 2: high risk It increases the risk of hypotension, 
priapism, headache, and visual 
disturbances. Doses should be 
adjusted: sildenafil to 25 mg/48 
hours, tadalafil to 10 mg/72 hours, 
and vardenafil to 2.5 mg/72 hours 
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Opioid analgesics 
(Armstrong & Cozza, 
2003a, 2003b) 
 
 Oxycodone 
 Buprenorphine 
 
2: high risk 
 
 
 
 
No 
information 
available on 
clinically 
relevant 
interactions
Inhibition of CYP3A4 and 
metabolism of oxycodone and 
buprenorphine, increasing plasma 
concentrations and the likelihood 
of toxic effects (sedation and 
respiratory depression) 
 
Dihydrocodeine, hydrocodone, and 
codeine are pro-drugs and require 
activation by CYP2D6 or 
glucuronyl-transferase. Therefore, 
delavirdine may inhibit the 
metabolism and the formation of 
the active compound and, 
consequently, the pharmacological 
effect of these drugs 
 Dihydrocodeine 
 Hydrocodone 
 Codeine 
3: medium 
risk 
Antidepressants reuptake 
inhibitors (SSRI) 
(Caballero & Nahata, 
2005; Currier et al., 2004; 
DeSilva et al., 2001; 
Isbister & Buckley, 2005; 
Tseng  & Foisy, 1999)  
 Fluoxetine 
 Fluvoxamine 
 Venlafaxine 
 Paroxetine 
 Sertraline 
No 
information 
available on 
clinically 
relevant 
interactions 
with 
delavirdine 
2: high risk Efavirenz, in cases of deficiency of 
CYP2D6, may inhibit CYP2C9 and 
CYP2C19, which can lead to 
increased levels and toxicity of 
SSRIs (serotonin syndrome). We 
recommend using half or the 
lowest dose possible of these two 
drugs, adjusting the dose in terms 
of their effectiveness and safety 
Warfarina (acenocumarol) 2: high risk Efavirenz 
induces 
warfarin 
metabolism
With delavirdine it increases the 
risk of bleeding. It is recommended 
dose adjustment and monitoring of 
INR
Cisapride a 2: high risk 2: high risk More likelihood of increasing QTc 
interval on the electrocardiogram 
and cardiac arrhythmias, as well as 
gastrointestinal disturbances and 
dizziness
Raltegravir (Aberg, 2008) No 
information 
available 
2: high risk The Cp of raltegravir is reduced 
when is co-administered with 
efavirenz
a Delavirdine, primarily through inhibition of CYP3A4, and efavirenz through inhibition of CYP3A4 and 
CYP2D6, may decrease the metabolism of these drugs, which can cause increased plasma 
concentrations and toxicity. 
Table 3. General interactions due to enzyme inhibition by inhibitors of non-nucleoside 
transcriptase (DeMaat et al., 2003; DHHS, 2011; Krikorian & Rudorf, 2005; Piscitelli  & 
Gallicano, 2001; Tran et al., 2001) 
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From a practical perspective and specifying the type of PI, it is generally recommended to 
avoid the following combinations (level 1 or level 2: very high risk or high risk): (DHHS, 2011) 
 Indinavir with: atazanavir, simvastatin or lovastatin, amiodarone, cisapride, pimozide, 
astemizole or terfenadine, midazolam or triazolam, ergotamine, ergonovine, or methyl 
ergonovine. 
 Ritonavir (alone or with another PI) with: voriconazole (with a ritonavir dose higher 
than 400 mg/12 hours), fluticasone, simvastatin or lovastatin, amiodarone, flecainide, 
propafenone, or quinidine, cisapride, pimozide or clozapine, trazodone or nefazodone , 
astemizole or terfenadine, midazolam or triazolam, ergotamine, ergonovine or 
methylergonovine. 
 Saquinavir with: simvastatin or lovastatin, cisapride, pimozide, astemizole or 
terfenadine, midazolam or triazolam, ergotamine, ergonovine, or methyl ergonovine. 
 Lopinavir/ritonavir with: fluticasone, simvastatin or lovastatin, flecainide or 
propafenone, cisapride, pimozide, astemizole or terfenadine, midazolam or triazolam, 
ergotamine, ergonovine, or methyl ergonovine. 
 Nelfinavir with indinavir, irinotecan, simvastatin or lovastatin, cisapride, pimozide, 
astemizole or terfenadine, midazolam or triazolam, ergotamine, ergonovine or 
methylergonovine. 
 Atazanavir with: simvastatin or lovastatin, cisapride, pimozide, astemizole or 
terfenadine, midazolam or triazolam, ergotamine, ergonovine, or methyl ergonovine. 
 Amprenavir (same for the fosamprenavir) with: simvastatin or lovastatin, cisapride, 
pimozide, astemizole or terfenadine, midazolam or triazolam, ergotamine, ergonovine, 
or methyl-ergonovina. ( Wire et al., 2006) 
 Tipranavir with: fluticasone, simvastatin or lovastatin, amiodarone, flecainide, 
propafenone, or quinidine, cisapride, pimozide, astemizole or terfenadine, midazolam 
or triazolam, ergotamine, ergonovine, or methyl-ergonovina.( Boffito et al., 2006)  
From a practical perspective and specifying the type of NNRTIs, it is generally 
recommended to avoid the following combinations (level 1 or level 2: very high risk or high 
risk): (DHHS, 2011)  
 Delavirdine with: amprenavir or fosamprenavir, simvastatin or lovastatin, cisapride, 
astemizole or terfenadine, alprazolam, midazolam or triazolam, ergotamine, ergonovine 
or methyl ergonovine. 
 Efavirenz with: voriconazole, cisapride, astemizole or terfenadine, midazolam or 
triazolam, ergotamine, ergonovine or methyl ergonovine. 
Related to PIs and NNRTIs Di, it is important to note that for delavirdine, its combination 
with amprenavir or fosamprenavir can cause a decrease in the levels and effects of 
delavirdine. (Tran et al., 2001; Wire et al., 2006) Additionally, some studies have shown a 
possible interaction between fosamprenavir with lopinavir/ritonavir, in fact mediated by a 
two-way increase in CYP3A4 and/or P-glycoprotein (P-gp) metabolic activity by 
fosamprenavir and lopinavir. (Huang et al., 2001; Taburet et al., 2004; Tranet al., 2002) This 
interaction is associated to a 50-60% decrease in lopinavir plasma concentration, and a 60-
70% decrease in amprenavir levels (ritonavir levels do not change significantly). 
Consequently, combining these 3 PIs may be inappropriate, due to a high probability of 
generating a virologic failure (Kashuba et al., 2005) (level 2: high risk). The negative effect of 
this interaction is not neutralized by increasing ritonavir dose from 100 to 200 mg/12 hours; 
while this strategy is associated with increased gastric problems associated to the use of 
ritonavir. (Mauss et al., 2004)   
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On the other hand, it seems that the combination atazanavir with lopinavir/ritonavir does 
not generate this problem (although decreased levels of lopinavir by the action of atazanavir 
may occur (Colombo et al., 2006), which is considered a double pharmacokinetic extension 
(boosted) with PI, useful in a certain group of patients. (Ribera et al., 2006)  Contrary to this 
effect (of atazanavir on lopinavir levels), when using a saquinavir/ritonavir and atazanavir 
(1.600/100 and 200 mg) an increase in saquinavir plasma and cellular levels is observed 
(without effect on ritonavir). Therefore, it is believed that adding atazanavir 200 mg/day to 
saquinavir/ritonavir 1.600/100 mg/day may be a good strategy for patients in who the 
Cpss are under the minimum effective one. (Ford et al., 2006)   
Due to it is common used of this group of drugs in HIV infected patients receiving 
antiretroviral therapy; it is important focus following drugs therapeutic class:  
Statins. The simultaneous use of PI or delavirdine with statins (lovastatin≈ simvastatin > 
atorvastatin > rosuvastatin ≈ fluvastatin ≈ pravastatin) increases the risk of myopathy, 
rhabdomyolysis, and even death. (Hare et al., 2002) Thus, for atorvastatin the lowest 
possible doses are recommended. Also, it is suggested to monitor muscle toxicity signs and 
symptoms or to use statins less likely to have this type of interaction, such as pravastatin, 
fluvastatin or rosuvastatin from. (Benesic et al., 2004; DHHS, 2011; Fichtenbaum et al., 2002; 
Fichtenbaum & Gerber, 2002; Jacobson, 2004; Sax, 2006) In this regard, statins (simvastatin, 
lovastatin, and atorvastatin, except pravastatin, fluvastatin, and rosuvastatin) are 
metabolized by CYP3A4 and, therefore, their use should be avoided in patients using PIs, 
especially ritonavir, atazanavir and saquinavir. Both metabolism and levels of pravastatin, 
as well as, most likely, fluvastatin and rosuvastatin are slightly affected by the combined use 
of ritonavir, indinavir, atazanavir, saquinavir, and nelfinavir and therefore they could be 
combined in patients receiving cART or HAART. (Aberg et al., 2006; Bays, 2006; Benesic et 
al., 2004; Cooper et al.,  2003; Jacobson, 2004; Sudano et al., 2006). However, in some cases it 
may be necessary to increase the dose of pravastatin, as appears likely in the case of 
nelfinavir. (Aberg et al., 2006)  
Selective serotonin reuptake inhibitors (SSRI). The use of ritonavir (alone or in combination 
with another PI) by inhibiting CYP2D6 and efavirenz by inhibiting CYP2C9 and CYP2C19, 
when a deficit of CYP2D6 exists, may lead to increased levels and toxic effects of SSRIs 
(fluoxetine, fluvoxamine, venlafaxine, paroxetine and, sertraline). Particularly, it may lead to 
the development of serotonin syndrome (DeSilva et al., 2001). Therefore, it is advisable to use 
half the dose or the lowest dose possible of these drugs, setting the dose in terms of their 
effectiveness and safety. (DHHS, 2011) Additionally, citalopram, and possibly escitalopram 
and sertraline, due to their pharmacological properties (low metabolism and minimal effect on 
CYP activity), are considered the most suitable option in patients receiving cART or HAART. 
(Caballero & Nahata, 2005; Currier et al., 2004; DHHS, 2011; Kashuba, 2005) 
Generally, serotonin syndrome is a disorder caused by an increase in serotonin levels, 
resulting in cognitive disorders (lethargy, confusion, coma, agitation, hallucinations, and 
seizures); neuromuscular activity disorders (myoclonus, tremor, hyperreflexia, rigidity, 
hyperactivity); autonomic nervous system disorders (hypotension or hypertension, 
tachycardia, chills, hyperthermia, diaphoresis, diarrhea, salivation, abdominal pain, 
tachypnea) (Isbister & Buckley, 2005). In a patient under treatment with a SSRI (or other 
drugs with serotonergic activity in the central nervous system), such change can occur due 
to pharmacodynamic interactions (simultaneous treatment with other drugs that increase 
serotonin activity or agonist) or to pharmacokinetic interactions (treatment with an CYP2D6 
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inhibitor or because of a situation leading to an increase in serotonin levels and effects). 
(DeSilva et al., 2001; Tseng & Foisy, 1999)  
3.2 Drug interactions mediated mainly by enzymatic inhibition of PIs and NNRTIs with 
other known enzyme inhibitors (for some drugs metabolism inhibition may occur 
while for others may occur metabolism induction) 
Since PIs and NNRTIs are metabolized by CYP3A, strong inhibitors of CYP3A isoenzyme 
may inhibit its metabolism, increase plasma levels and therefore the risk of developing 
adverse drug reactions or toxicities. In these cases, generally, inhibition is bidirectional (the 
strong inhibitors may increase the PIs and NNRTIs levels and toxicity as well as PIs and 
NNRTIs may increase the inhibitors plasma concentrations and toxicity). However, in some 
cases the interaction can be in one direction, while in others both NNRTI metabolism 
inhibition (by the known inhibitor) and known inhibitor metabolism induction (by the 
NNRTIs) may occur, especially with efavirenz and nevirapine. In table 4 (for PIs) and table 5 
(for NNRTIs) the most relevant interactions of this type are included.  
Due to it is important some examples of the one-way drug interactions mediated mainly by 
enzymatic inhibition of PIs and NNRTIs are detailed:  
Azoles antifungals 
 Azoles antifungals (ketoconazole, itraconazole, fluconazole, voriconazole) with 
amprenavir. Antifungal may inhibit amprenavir hepatic metabolism (and probably 
fosamprenavir metabolism), which can lead to an increase in their levels, although such 
increase does not seem to be clinically relevant (level 3: medium risk). (Vourvahis & 
Kashuba, 2007) 
 Fluconazole with tipranavir/ritonavir. Fluconazole causes an increase in the area under 
the curve. In any case, similar to what happens when PIs are used with azoles 
antifungals; it is advisable to monitor the hepatic function and not to exceed a dose of 
200 mg/daily fluconazole. (DHHS, 2011)  
 Ketoconazole with delavirdine. Ketoconazole may increase delavirdine levels (Level 3: 
medium risk), (DHHS, 2011) but ketoconazole levels do not change significantly. 
Macrolides and immunosuppressants 
 Clarithromycin with amprenavir (and probably fosamprenavir). Clarithromycin 
produces an 18% an increase in the area under the curve of amprenavir, while the effect 
of PI on macrolide levels is lowest. (Brophy et al., 2000) 
 Immunosuppressants with efavirenz or nevirapine. Cyclosporine and tacrolimus may 
increase the levels and toxicity of these two NNRTIs. It is thus recommended to 
monitor toxicity signs and symptoms of these drugs and, if required, to adjust its dose 
(Level 3: medium risk). (Jain et al., 2002; Vogel et al., 2004)  
3.3 Drug interactions due to enzyme induction of NNRTIS (Back et al., 2003; 
Bergshoeff et al., 2005; DHHS, 2011; Kashuba, 2005; Krikorian & Rudorf, 2005; 
Mildvan et al., 2002; (Pérez et al., 2009; Piscitelli & Gallicano, 2001; Saraga et al.,  
2006; Young, 2005)
 
Efavirenz and nevirapine due to their ability to increase the hepatic metabolism may cause a 
decrease in PIs levels and consequently therapeutic failure. Therefore, in general, using a 
single PI with efavirenz (in particular) or nevirapine is considered contraindicated (level 2 
interaction: high risk). For example, efavirenz can cause a 39% reduction in the minimum 
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Group drugs or 
drugs affected 
Clinical 
relevance of the 
bidirectional 
inhibition: level
Comments and suggestions 
Azole antifungals a 
(Polk et al., 1999; 
Vourvahis & 
Kashuba, 2007)  
 Ketoconazole 
 Itraconazole 
 Fluconazole 
   
  
2: high risk 
 
 
 
 
Except for amprenavir and fosamprenavir, there is a 
bidirectional increase in the levels of antifungal and 
PIs, which can lead to toxicity problems. It is 
recommended using up to 200 mg/day of 
ketoconazole or 200-400 mg/day of itraconazole. In 
the case of fluconazole combination with tipranavir / 
ritonavir an increase in levels of tipranavir, without 
significant changes in fluconazole is observed. 
(Vourvahis & Kashuba, 2007)  
The coadministration of darunavir and ketoconazole 
increase the plasma concentrations of both drugs, 
creating the same toxic effects (Sekar et al., 2008)  
 Voriconazole 3: medium risk 
Macrolides a   
 Erythromycin 
 Clarithromycin 
 
 
 
 
2: high risk 
 
Except for amprenavir and fosamprenavir, a 
bidirectional increase in the levels of macrolides and 
PIs is generated, which can lead to toxicity problems. 
Macrolides may increase QTc interval on the 
electrocardiogram. It is recommended to use 
maximum 1 g / day of these antibiotics (for 
clarithromycin it is suggested to reduce 50-75% in the 
level, if the patient has a creatinine clearance <60 ml 
/ minute). In general, it is considered that using 
erythromycin with a strong inhibitors of CYP3A4 
should be avoided (Ray et al., 2004) 
Immuno-
suppressants a 
(Jain et al., 2002; 
Vogel et al., 2004) 
  Cyclosporine 
 
 Tacrolimus 
 
 
2: high risk 
 
Increased levels and toxicity of immunosuppressants 
can be generated, so it is recommended to monitor 
plasma levels and to adjust the treatment regime. In 
the case of nelfinavir/tacrolimus combination it is 
recommended to reduce by 50% the dose of the 
immunosuppressant (Jain et al., 2002). In the case of 
cyclosporine with lopinavir / ritonavir, a 5% initial 
reduction is recommended in cyclosporine dose (a 
reduction of up to 20%) may be necessary. (Vogel et 
al., 2004) Cyclosporine and tacrolimus may increase 
the levels and toxicity of PIs and therefore it is 
recommended to monitor signs and symptoms of 
toxicity, and if required, to adjust the dose 
a PIs can inhibit CYP3A4 and may decrease the metabolism of these drugs, which can cause increased 
plasma concentrations and toxicity. In turn, these drugs, also due to CYP3A4 inhibition, may decrease 
the metabolism of PIs and increase plasma concentrations and toxicity. 
Table 4. Clinical relevant bidirectional drug interactions mediated by PIs enzyme inhibition 
with other known drugs (Brophy et al., 2000; DHHS, 2011; Kashuba, 2005a, 2005b; Krikorian 
& Rudorf, 2005; Robertson et al., 2005b; Young, 2005) 
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Drug group or drugs 
affected  
Clinical relevance: level Comments and 
suggestions Delavirdine Efavirenz Nevirapine
Azole antifungals a 
 Ketoconazole 
 
 
3: medium 
risk 
 
No 
information 
available 
 
 3: medium 
risk 
 
 
 
With Delavirdine: 
Delavirdine levels 
increased with no 
change in ketoconazole 
levels. 
With nevirapine: 
increased levels of 
nevirapine and 
decreased ketoconazole 
levels
 Itraconazole 3: medium 
risk 
No 
information 
available 
No 
information 
available 
In general, slight clinical 
relevance 
 Fluconazole No 
significant 
changes 
 
No 
information 
available 
 
2: high risk
 
With nevirapine: 
increased levels and 
potential liver toxicity of 
nevirapine and no 
changes on fluconazole  
 Voriconazole 3: medium 
risk 
2: high risk 
 
3: medium 
risk 
 
With delavirdine: 
increased levels of both 
drugs. The toxic effects 
of both drugs should be 
monitored. 
Efavirenz and 
nevirapine:  NNRTI 
levels increased and 
decreased levels 
voriconazole 
Macrolides a 
 Erythromycin 
 Clarithromycin 
2: high risk 2: high risk No 
information 
available 
A bidirectional increase 
in the levels of 
macrolides and 
delavirdine and 
efavirenz, which may 
lead to problems of 
toxicity of macrolides 
and NNRTIs 
Immunosuppressant
s 
 
 Cyclosporine 
 
 Tacrolimus 
3: medium 
risk 
3: medium 
risk 
3: medium 
risk 
Immunosuppressants 
inhibit the metabolism 
of efavirenz and 
nevirapine. In addition, 
there are reports of 
decreased levels of 
cyclosporine by 
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efavirenz, so it is 
recommended to 
monitor the levels of 
immunosuppressants 
(Tseng et al., 2002) 
Pimozide (DHHS, 
2011)  
 
No 
information 
available 
 
2: high risk 
 
No 
information 
available 
 
Efavirenz with drugs 
primarily metabolized 
by CYP3A4 may 
increase plasma 
concentrations of drugs, 
due to a weak inhibitory 
effect on this enzyme. 
Recommendation: There 
may be potential for 
serious or life-
threatening reactions 
such as cardiac 
arrhythmias with 
pimozide, so it is not 
recommended for use 
concomitantly 
a NNRTIs may inhibit CYP3A4 and may decrease the metabolism of these drugs, which can cause 
increased plasma concentrations and toxicity. In turn, these drugs, also due to CYP3A4 inhibition, may 
decrease the metabolism of NNRTIs and increase plasma concentrations and toxicity.  
Table 5. Clinical relevant bidirectional drug interactions mediated by enzyme inhibition 
(induction in some cases) of NNRTIs with other known enzyme inhibitors (Brophy et al., 
2000; Jain et al., 2002; Krikorian & Rudorf, 2005; Piscitelli & Gallicano, 2001; Polk et al., 1999; 
Ray et al., 2004; Robertson et al., 2005b; Sekar et al., 2008; Vogel et al., 2004; Vourvahis & 
Kashuba, 2007; Young, 2005)   
lopinavir steady state concentration. (Dailly et al., 2005; Solas et al., 2004) The use of another 
low-dose PI as a pharmacokinetic extension agent (boosted), for instance ritonavir, is a 
strategy to counter this problem. (Acosta, 2002; Rathbun & Rossi, 2002; Zeldin & Petruschke, 
2004) When using atazanavir with efavirenz it is recommended to add 100 mg of ritonavir to 
the usual dose (300 mg/24 hours). For lopinavir/ritonavir and efavirenz, 
lopinavir/ritonavir should be increased from 400/100 mg/12 hours (3 capsules) to 533/133 
mg/12 hours (4 capsules) without change in the efavirenz dose. (DHHS, 2011; Solas et al., 
2004; Dailly et al., 2005). For pediatric patients, in order to compensate the induction of 
efavirenz hepatic metabolism, it is suggested to increase the lopinavir/ritonavir dose to 
300/75 mg/m2 twice daily. (Dailly et al., 2006) Related to this topic, some studies have 
shown that cimetidine may be useful as a pharmacokinetic extension agent (effect similar to 
ritonavir) when combined with saquinavir. (Boffito et al., 2002)  
Besides the effect of efavirenz and nevirapine on PIs levels, these ITINNs, (DeJesus et al., 
2006) efavirenz (mainly) and nevirapine may increase metabolism, lower levels and cause 
therapeutic failure with various medications, such as statins (Gerber et al., 2005) and 
warfarin. In table 6 the most relevant interactions due to enzyme induction mediated by 
these two NNRTIs are included. 
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Drug group or 
drugs affected 
Clinical relevance: level Comments and suggestions 
Delavirdine Efavirenz Etravirine 
Protease inhibitors 
(PI) a  
 Indinavir (IDV) 
(Harris et al., 
2006b) 
 Nelfinavir (NFV)
 Ritonavir (RTV) 
 Amprenavir 
(APV) 
 Tipranavir (TPV) 
 Lopinavir/Riton
avir (LPV/r) 
(Bergshoeff et al., 
2005; Dailly et al., 
2005; Solas et al., 
2004)  
2: high risk 2: high risk 2: high risk In general, the use of a single PI 
with efavirenz (specially) or 
nevirapine should be avoided. 
Efavirenz may decrease by 39% 
the minimum concentration of 
lopinavir. The dose should be 
increased to 533/133 mg/12 
hours 
Saquinavir (SAQ) 
(Boffito et al., 2002) 
4: low risk 
(Fletcher et 
al., 2000) 
3: medium 
risk (Baker, 
1998) 
2: high risk Concomitant use of etravirine 
with saquinavir causes a 
decrease of the saquinavir 
plasma concentrations, due to 
etravirine induction effect on 
CYP3A4. (Etravirine, 2006; 
Harris et al., 2006b)  
Atazanavir (ATZ) 
(Mullin et al., 2004) 
2: high risk
 
2: high risk
 
1: Very 
high risk 
It is recommended to add 100 
mg of ritonavir.   
The plasma concentration of 
atazanavir is reduced by 38% if 
it is administered concomitantly 
with etravirine. 
Recommendation: Concomitant 
use of etravirine with 
atazanavir/ritonavir. (Aber, 
2008) 
Fosamprenavir 
(f-APV) ( Back et 
al, 2003)  
2: high risk
 
2: high risk
 
1: Very 
high risk 
Nevirapine may decrease 
plasma concentrations between 
25 and 35% 
Fosamprenavir plasma 
concentration is decreased by 
77% if it is administered 
concomitantly with etravirine. 
Recommendation: avoiding 
concomitant administration of 
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etravirine with fosamprenavir. 
(Holdich et al., 2007)  
Darunavir  No 
information
available 
2: high risk No 
information 
available 
Efavirenz may decrease plasma 
concentrations of darunavir 
(Schöller et al., 2007) 
Statins a(Gerber et 
al., 2005; Sekar et 
al., 2007a) 
 Simvastatin 
 Atorvastatin  
 Pravastatin  
 Lovastatin 
 Rosuvastatin 
3: medium 
risk 
3: medium 
risk 
3: medium 
risk 
Possible reduction effect of these 
hypolipidemic. Pharmacological 
response should be traced and 
dose adjusted, where necessary is 
recommended to monitor 
parameters the effectiveness of 
lovastatin (lipid profile) and if 
necessary make an adjustment in 
medication dosage 
Methadone (Altice 
et al., 1999; Bruce et 
al., 2006; Clarke et 
al., 2001; Stocker et 
al., 2004)  
2: high risk 2: high risk No 
information 
available 
See text: methadone and 
efavirenz (nevirapine) 
Warfarina a   3: medium 
risk 
3: medium 
risk 
No 
information 
available 
Monitoring INR 
Ethinyl estradiol a  
(oral contraceptives) 
(Mildvan et al, 2002) 
2: high risk 2: high risk No 
information 
available 
Additional contraceptive 
method should be used (barrier 
method, for example) 
Valproic acid 
(Saraga et al., 2006) 
2: high risk No 
information 
available 
No 
information 
available 
Efavirenz may decrease 
valproate concentrations by 
induction of glucoronosil 
diphosphate transferase 
Macrolides 
 Clarithromycin 
(Schöller et al., 
2006b)  
 Erythromycin 
No 
information 
available 
No 
information 
available 
2: high risk Etravirine may decrease the 
drugs plasma concentrations, 
because it exerts on enzyme 
induction of CYP3A4 
Maraviroc 
 
No 
information
available 
 
2: high risk 
 
3: medium 
risk 
 
Efavirenz is an inducer of 
CYP3A4 metabolism which can 
lead to reduced plasma 
concentrations of maraviroc. 
Recommendation: In the 
presence of enzyme inducers 
such as efavirenz, maraviroc 
may be increased to 600 mg 
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twice daily (Abel et al., 2008) 
Simultaneous administration of 
etravirine and maraviroc causes 
a decrease in plasma 
concentrations of maraviroc 
(Cmin decreased 29%, Cmax by 
60% and AUC by 53%).  
Recommendation: dose 
adjustment (Davis et al., 2007) 
NNRTI 
 Efavirenz  
 Nevirapine 
No 
information 
available 
No 
information 
available 
2: high risk 
 
Concomitant use of etravirine 
with nevirapine and efavirenz 
can cause a decrease in plasma 
concentrations of etravirine and 
its therapeutic effect (Kakuda et 
al., 2006)  
Raltegravir  No 
information
available 
2: high risk 2: high risk Concomitant administration of 
etravirine and raltegravir with 
efavirenz can cause a decrease 
in plasma concentration of 
raltegravir. Cmin is reduced by 
34% and AUC by 10%. 
(Anderson et al., 2008; Menard 
et al., 2009; Wittkop et al., 2009)  
Sildenafil No 
information 
available 
No 
information 
available 
3: medium 
risk 
 
Coadministration of etravirine 
with sildenafil can cause a 
decrease in sildenafil 
concentrations by 57%. 
Recommendation: 
dose adjustment of sildenafil 
Pérez et al., 2009)  
Buprenorphine No 
information
available 
No 
information 
available 
2: high risk Coadministration of efavirenz 
with buprenorphine may 
decrease plasma concentrations 
of its active metabolite, 
norbuprenorphine, due to the 
inductive effect exerted by the 
efavirenz on CYP3A4 
(McCance-Katz et al., 2006) 
a Efavirenz, in particular, and nevirapine can primarily induce CYP3A4 and increase the metabolism of 
these drugs, which can cause a decrease plasma concentrations and therapeutic effects. 
Table 6. Clinical relevant drug interactions due to enzyme induction mediated by NNRTIs 
(DeJesus et al., 2006; DHHS, 2011; Krikorian & Rudorf, 2005; Young, 2005)   
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Methadone and efavirenz (nevirapine). Efavirenz and nevirapine may reduce methadone 
area under curve (AUC) by 57% and 46%, respectively. (Altice et al., 1999)  Therefore, when it 
is necessary to use methadone in patients that are using these NNRTIs, it is advisable to 
gradually increase the opiate dose from 10 to 10 mg, (Stocker et al., 2004) adjusting it based on 
effectiveness and safety parameters. Particular attention must be paid to withdrawal clinical 
manifestations. Withdrawal manifestations usually appear 7-10 days after initiating treatment 
with NNRTI and must not be confused with neurological toxicity symptoms associated with 
efavirenz (dizziness, headache, insomnia, concentration difficulty, nightmares, and agitation) 
that may occur within 1-2 days of starting treatment with efavirenz and which may be present 
during 14-28 days. (Bruce et al., 2006) Additionally, at sites with a suitable infrastructure, 
plasma levels of methadone can be monitored, aiming to reach a concentration of 400 and 250 
micrograms/mL for (R, S)-methadone and (R) – methadone, respectively. (Bruce et al., 2006; 
Clarke et al., 2001; DHHS, 2011; Stocker et al., 2004) 
Ritonavir as enzymatic inductor. Ritonavir, alone or in combination with other PIs, due to 
its ability to induce mainly glucuronyl-transferase and, to a lesser extent CYP2B6, which 
may produce ineffectiveness of some drugs: 
 Ethinyl estradiol (oral contraceptive component). The contraceptive effect may be 
diminished when used simultaneously with ritonavir. (Ouellet et al., 1998) It is 
therefore advisable to inform the patient of the need to use a barrier method as a 
complementary birth control method (DHHS, 2011) (level 2: high risk). 
 Thyroid hormones. It may cause metabolic inactivation of thyroid hormones and treatment 
failure (level 2: high risk). It is therefore recommended to monitor and adjust the levels of 
thyroid hormones in patients under treatment with ritonavir. (Touzot et al., 2006) 
 Lamotrigine. It produces a decrease in anticonvulsant plasma levels, which can lead to 
ineffective treatment (level 2: high risk). It may be necessary to double lamotrigine dose 
in order to achieve therapeutic levels. (Van der Lee et al., 2006) 
 Bupropion. It causes a decrease both in bupropion levels and its metabolite (hydroxy-
bupropion), which could lead to ineffective treatment (Level 3: medium risk) and the 
need to double bupropión dose. (Hogeland et al., 2007) However, in theory, ritonavir 
can also act as an inhibitor of this isoenzyme and, therefore, increase concentrations of 
bupropion, so caution is advised until more data are available. 
3.4 Drug interactions mediated by known enzyme inducers and consequences on PIs 
and NNRTIs efficacy (Benator et al., 2007; DHHS, 2011; Hamzeh et al., 2003; Kraft et 
al., 2004; Krikorian & Rudorf, 2005; Lim et al., 2004; Mullin et al., 2004; Romanelli & 
Pomeroy, 2003; Young, 2005)  
The pharmacological effect of PIs and NNRTIs may be diminished and thus  may appear 
therapeutic failure, associated with the emergence of resistance, when these ARV are 
combined or used simultaneously with known enzyme inducers (rifampicin, rifabutin, 
phenobarbital, primidone, carbamazepine, phenytoin), including St. John's wort. Rifabutin, 
a drug in the same family as rifampicin (rifamycins), is also characterized by inducing the 
metabolism of certain drugs, although to a lesser degree than rifampicin. (Finch et al., 2002)  
3.4.1 Interactions of rifamycins with protease inhibitors (PIs) or with non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) 
Rifampicin and PIs. (Blumberg et al., 2003; Finch et al., 2002; Sekar et al., 2010; Spradling et 
al., 2002) In general, the use of rifampicin (rifabutin is preferred due to their lesser inductive 
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effect than rifabutin) with a single PI, including the most recent, such as amprenavir and 
atazanavir, is considered contraindicated (level 1: very high risk), because in most cases, 
rifampicin produces non-efficacy PIs concentrations. Besides, most treatment guidelines 
for HIV/AIDS patients extend this contraindication even to PIs combined with ritonavir 
used as a pharmacokinetic extension agent (enhancer). (DHHS, 2011) However, for 
saquinavir, (Rolla et al., 2006) atazanavir, (Burger et al., 2006) and lopinavir, (La Porte et 
al., 2004) some studies show that adding ritonavir may counteract such effect in to some 
extent. In these cases, both saquinavir/ritonavir dose must be adjusted to 400/400 mg twice 
daily, (Aaron et al., 2004; de Jong et al., 2004; Rolla et al., 2006;) and lopinavir/ritonavir to 
400/400 mg/12 hours or to 800/200 mg/12 hours. (Aaron et al., 2004; de Jong et al., 2004; La 
Porte et al., 2004)  
Regarding the concomitant administration of saquinavir/ritonavir (1000/100 mg once daily) 
with rifampicin, because of some reports of liver toxicity, it is recommended to avoid such a 
combination. (Kashuba, 2005) Additionally, some studies show that in order to achieve 
saquinavir adequate levels, when saquinavir is used in combination with ritonavir, it is 
advisable to use doses higher than 1.600/200 mg/day of this combination; (Ribera et al., 
2007) however this situation could further increase the likelihood of liver toxicity problems. 
With respect to the advisable rifampicin dose (despite the possible inhibitory effect of PI), 
changes are not recommended, but liver functioning must be monitored. (La Porte et al., 
2004; de Jong et al., 2004; Aaron et al., 2004) For amprenavir (Polk et al., 2001) even with 
low-dose ritonavir (100 or 200 mg/day), their use in combination with rifampicin is 
contraindicated (level 1: very high risk). (DHSS, 2011)  
Rifampicin and NNRTI. (Finch et al., 2002; de Jong et al., 2004; Ribera et al., 2001; 
Ramachandran et al., 2006; Weiner et al., 2005) In general, the use of rifampicin together 
with delavirdine is considered contraindicated (Borin et al., 1997) (level 1: very high risk). 
When it needs to use simultaneously rifampin with efavirenz, it is recommended to increase 
the NNRTI dose from 600 to 800 mg/day. (DHHS, 2011; Matteelli et al., 2007) However, 
some studies conducted with patients weighing 50 kg in Thailand and infected with HIV 
and tuberculosis, treated with rifampicin and HAART, indicate that the use of the standard 
efavirenz dose (600 mg/day) may be enough to reach the desired levels and effects with 
NNRTI at 24 and 48 weeks. (Manosuthi et al., 2005, 2006) Similarly, results achieved in 
African patients support the use of efavirenz 600 mg/day. (Friedland et al., 2006) 
Additionally, there are some reports of toxicity with efavirenz at doses of 800 mg/day. 
(Brennan et al., 2005) Therefore, it is believed that with black patients weighing less than 55 
kg, as well as with Hispanic or Asian patients who show evidence of susceptibility to 
efivarenz toxic effects, it is recommended to use a 600 mg/day dose of this NNRTI. 
(Matteelli et al., 2007) Thus, when it is indicate to use rifampicin with efavirenz no 
adjustments are recommended in the dose of rifampicin. 
Consequently, in general: a) for patients receiving HAART, rifabutin should preferred to the 
use of for rifampicin, due to its significantly lower enzyme-inducing effect, b) the use of 
single PIs with rifampicin should be avoided; c) some studies show that rifampicin could be 
used with saquinavir, atazanavir, and lopinavir enhanced with ritonavir, but it is needing 
more evidence on the effectiveness and safety of such combinations, d) the use of 
delavirdine in conjunction with rifampicin or rifabutin is considered absolutely 
contraindicated, and e) in most cases where rifabutin or rifampicin is combined with PIs, 
dosage must be adjusted and  potential toxicity must be monitored, particularly liver 
toxicity due to rifamycins. 
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Hypericum (St. John's wort) as enzyme inducer and ARV drugs. In general, the 
combination of this herbal antidepressant with PIs or with NNRTIs, due to high probability 
of generating therapeutic failure, is considered contraindicated (level 1: very high risk). 
Thus, there are several reports of therapeutic failure of ritonavir and nevirapine, associated 
with the use of this herbal product. (Izzo, 2004; Winston & Boffito, 2005; Zhou et al., 2004) 
This substance may induce both the systemic metabolism by CYP3A4, and the presystemic 
metabolism by intestinal or hepatic CYP3A4; additionally it may induce P-gp activity 
(bioavailability related interactions). (Lee et al., 2006)  
Table 7 contains details of interactions produced by rifamycins (rifampin and rifabutin), and 
table 8 contains detailed information on interactions mediated by traditional anticonvulsants. 
3.5 Drug interactions related to bioavailability  
3.5.1 Drug interactions related to changes in gastrointestinal pH  
In general, an increased gastrointestinal pH may affect the amount absorbed of delavirdine, 
indinavir, fosamprenavir, tipranavir, (Vourvahis & Kashuba, 2007) and atazanavir. (DeSilva 
et al., 2001; DHHS, 2011; Tomilo et al., 2006) However, it is basic to clarify some aspects: 
 Concomitant administration of atazanavir with proton-pump inhibitors (omeprazole, 
lansoprazole, pantoprazole) (Tomilo et al., 2006) is not recommended (Level 2: high 
risk). The use of delavirdine with H2 antihistamines (cimetidine, ranitidine, famotidine, 
and nizatidine) and with proton-pump inhibitors (level 2: high risk) is also not 
recommended, due to a decrease near to 90% of the amount absorbed and, 
consequently, to a reduction in antiretroviral plasma concentrations, which can lead to 
treatment failure. (DHHS, 2011) In the case of atazanavir, famotidine can be used as an 
alternative to omeprazole, spacing its administration about 10 hours. A similar result 
can be achieved by adding low-dose ritonavir (100 mg) at 300 mg/day atazanavir, or by 
increasing the dose to 400 mg/day of atazanavir. (Kashuba, 2005) 
Combined administration of antacids does not seem to significantly affect the amount 
absorbed of fosamprenavir, (Ford et al., 2005) or raltegravir; however it is recommended to 
separate the taking of the two drugs when they are used in pharmacological therapy. (Kiser 
et al., 2010)  
 
Drug group or drugs affected Clinical relevance: 
level 
Comments and suggestions 
(see text: rifampicin and PI 
and rifampicin and NNRTI) Rifampicin Rifabutin 
PIs a (Aaron et al., 2004; Benator et al., 
2007; Blumberg et al., 2003; Burger et 
al., 2006; DeJong et al. 2004; Finch et 
al., 2002; Hamzeh et al., 2003; Kraft et 
al., 2004; La Porte et al., 2004; Polk et 
al., 2001; Ribera et al., 2007; Rolla et 
al., 2006; Spradling et al., 2002)   
Ritonavir (Aaron et al., 2004; 
Blumberg et al., 2003; DeJong et al. 
2004; Finch et al., 2002; Spradling et 
al., 2002)  
1: very 
high risk 
2: high risk Adjust rifabutin dose  
150 mg/48 hours, with no 
change in ritonavir 
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Indinavir (Hamzeh et al., 2003, Kraft 
et al., 2004)  
1: very 
high risk 
2: high risk Adjust the dose of rifabutin 
150 mg/24 hours and 
indinavir at 1,000 mg/8 
hours 
Saquinavir (Aaron et al., 2004; 
Blumberg et al., 2003; DeJong et al. 
2004; Finch et al., 2002; Ribera et al., 
2007; Rolla et al., 2006; Spradling et 
al., 2002)   
1: very 
high risk 
 
2: high risk
 
Use usual dose of rifabutin 
(300 mg/day), with no 
change in saquinavir 
Nelfinavir (Aaron et al., 2004; 
Benator et al., 2007; Blumberg et al., 
2003; DeJong et al. 2004; Finch et al., 
2002; Spradling et al., 2002)   
1: very 
high risk 
 
2: high risk Adjust rifabutin dose 150 
mg/24 hours and nelfinavir 
to 1,000 mg/8 hours 
Atazanavir (Burger et al., 2006)  1: very 
high risk 
2: high risk Adjust rifabutin dose 150 
mg/48hours, with no change 
in atazanavir 
Amprenavir (Polk et al., 2001)  1: very 
high risk 
2: high risk Adjust rifabutin dose 150 
mg/24 hours, with no 
change in amprenavir 
Fosamprenavir (Aaron et al., 2004; 
DeJong et al. 2004)  
1: very 
high risk 
2: high risk Adjust rifabutin dose 150 
mg/24 hours, with no 
changes in fosamprenavir 
dose 
Tipranavir (Vourvahis & Kashuba, 
2007)  
1: very 
high risk 
2: high risk Adjust rifabutin dose 150 
mg/48hours, with no 
changes in tipranavir dose 
Lopinavir/ritonavir (Aaron et al., 
2004; La Porte et al., 2004; Spradling 
et al., 2002)  
1: very 
high risk 
2: high risk Adjust rifabutin dose 150 
mg/24 hours, with no 
changes in 
lopinavir/ritonavir dose 
Darunavir  2: high risk
 
2: high risk
 
The predominant metabolite 
of rifabutin (RFB) is 25-O-
desacetylrifabutin (desRFB), 
darunavir by inhibition of 
CYP3A4 may increase 
plasma concentrations of 
RFB, as well as its side effects 
(Sekar et al., 2010) 
Rifampin may significantly 
decrease the plasma 
concentrations of darunavir 
(Tibotec, 2008)  
Non-nucleosid transcriptase inhibitors 
(NNRTI)a   (DeJong et al. 2004; Finch 
et al., 2002; Friedland et al., 2006; 
Manosuthi et al., 2005, 2006; 
1: very 
high risk 
1: very high 
risk 
This combination is 
considered absolutely 
contraindicated 
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McCance-Katz et al., 2006; Matteelli 
et al., 2007a; Ramachandran et al., 
2006; Ribera et al., 2001)  
Delavirdine (Borin et al., 1997; 
DeJong et al. 2004; McCance-Katz et 
al., 2006; Spradling et al., 2002)  
Nevirapine (Benator et al., 2007; 
Blumberg et al., 2003; Borin et al., 
1997; Burger et al., 2006; Hamzeh et 
al., 2003; Kraft et al., 2004; La Porte et 
al., 2004; Polk et al., 2001; 
Ramachandran et al., 2006; Ribera et 
al., 2001, 2007; Rolla et al., 2006)  
2: high risk 3: medium 
risk 
In general terms, no dosage 
adjustment is recommended 
with rifabutin. With 
rifampicin it may be 
necessary to increase the 
dose from 200 mg/12 hours 
to 300 mg/12 hours, and to 
monitor liver function 
Efavirenz (Brennan et al., 2005; 
DeJong et al. 2004, Friedland et al., 
2006; Manosuthi et al., 2005, 2006; 
Matteelli et al., 2007a, 2007b; Weiner 
et al., 2005)  
2: high risk 2: high risk It is recommended to 
increase rifabutin dose to 
450-600 mg/day and to use 
the usual dose of efavirenz 
(600 mg/day) (Matteelli et 
al., 2007b) 
Etravirine (Abel et al., 2008)  2: high risk 3: medium 
risk 
Co-administration of 
etravirine with rifampicin 
causes a significant decrease 
in plasma concentrations of 
etravirine, due to inductor 
effect on CYP3A4 of 
rifampicin 
Co-administration of 
etravirine with rifabutin 
causes a decrease by 37% of 
plasma concentrations of 
etravirine 
Entry inhibitor:  
Maraviroc (Ogbuokiri, 2009)  
2: high risk 3: medium 
risk 
These drugs can reduce the 
maraviroc plasma 
concentrations by 66%. 
Recommendation: dose 
adjustment of maraviroc to 
600 mg 
 
a Rifampicin → rifabutin can induce CYP3A4 and increase the metabolism of these drugs, which can 
cause a decrease in plasma concentrations and virological response. In turn, some PIs or NNRTIs may 
modify the metabolism and concentrations or rifamycins, particularly by inhibition of CYP3A4, which 
can decrease their metabolism and increase plasma and concentrations and toxic effects of rifampicin 
and rifabutin, particularly liver and blood effects. 
Table 7. Clinical relevant drug interactions mediated by rifampicin and rifabutin  (DHHS, 
2011; Tran et al., 2001)   
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Drug group or 
drugs affected 
Clinical relevance: level Comments and suggestions  
Phenobarbital 
and primidone
Phenytoin Carbamazepine
Protease Inhibitors (PI) a (Lim et al, 2004; Mullin et al., 2004; Romanelli & Pomeroy, 2003)   
 Ritonavir 2: high risk 2: high risk 2: high risk Traditional anticonvulsants 
(except valproic acid) can 
cause ineffectiveness of PI 
(including their combination 
with low dose ritonavir). 
(Ogbuokiri, 2009)  
It is recommended the use of 
second-generation 
anticonvulsants (gabapentine, 
lamotrigine, vigabatrin and 
topiramate).  
Gabapentine, due to its 
pharmacological properties (it 
is not metabolized, it does not 
affect CYP activity), is 
considered the best option 
(Mullin et al., 2004; Romanelli 
& Pomeroy, 2003)  
 Indinavir 2: high risk 2: high risk 2: high risk 
 Saquinavir 2: high risk 2: high risk 2: high risk 
 Nelfinavir 2:high risk 2:high risk 2:high risk 
 Atazanavir 2:high risk 2:high risk 2:high risk 
 Amprenavir 2:high risk 2:high risk 2:high risk 
 Fosamprenavir 2:high risk 2:high risk 2:high risk 
 Tipranavir 2:high risk 2:high risk 2:high risk 
 Lopinavir/ 
ritonavir 
2:high risk 2:high risk 2:high risk Lopinavir / ritonavir may 
decrease the plasma 
concentrations of phenytoin, 
due to the induction of 
CYP2C9 
Non-nucleoside transcriptase inhibitors  (NNRTI) a (Mullin et al., 2004; Romanelli & Pomeroy, 
2003; Tran et al., 2001; Tseng  & Foisy, 1999)   
 Delavirdine 1: very high 
risk 
No 
information 
available 
1:very high 
risk 
Delavirdine with any of the 
traditional anticonvulsants 
(except valproic acid) is 
considered contraindicated. 
Traditional anticonvulsants 
(except valproic acid) can 
cause NNRTI ineffectiveness 
(Acosta, 2002)  
 Nevirapine 2: high risk No 
information 
available 
2:high risk 
 Efavirenz 2:high risk No 
information 
available 
2: high risk 
Entry inhibitor 
 Maraviroc 
(Ogbuokiri, 
2009)  
3: medium 
risk 
3: medium 
risk 
3: medium 
risk 
Traditional anticonvulsants 
(except valproic acid) can 
cause ineffectiveness of 
maraviroc 
Table 8. Clinical relevant drug interactions mediated by traditional anticonvulsants (DHHS, 
2011; Tran et al., 2001) 
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 Etravirine-Ranitidine. The concurrently use of etravirine and ranitidine for a period of 
eight days may cause a reduction in absorption of etravirine due to decrease of gastric 
(Schöller-Gyüre et al., 2008) acidity (level 3: medium risk).  
 Darunavir-Omeprazole/Ranitidine. Due to the absorption of some PIs is pH 
dependent gastric acid, antacids may inhibit absorption of PIs. However, some 
studies show that there are not clinically significant DIs between darunavir and 
omeprazole/ranitidine, thus no dose adjustment is required to concomitant 
administration. (Sekar et al., 2007b)  
 Absorption of delavirdine is noticeably decreased at pH values below 3. Therefore, its 
administration with antacids may cause a decrease on levels and effects (level 3: 
medium risk), and it is recommended to space its administration, at least an hour. (Tran 
et al., 2001)  
Broadly, didanosine in buffered tablets may decrease absorption, levels and efficacy of 
delavirdine and indinavir (as well of other drugs that requiring an acidic environment for 
absorption), due to didanosine excipients maintain gastric pH above 3. However, the 
addition of didanosine in a new dosage form (enteric-coated granules within capsules) 
minimizes this effect, as evidenced by the results of studies on drugs whose bioavailability 
may be decreased by interactions with antacids such as indinavir, ketoconazole, and 
ciprofloxacin. (Damle et al., 2002b) Furthermore, the buffered tablet effect cannot be 
generalized for drugs requiring an acidic pH for absorption, such as itraconazole or 
fluconazole, whose bioavailability is not altered when administered simultaneously with 
didanosine, regardless of dosage form used. (Damle et al., 2002a) 
Related to this type of mechanism, in general, food (drug-food interactions) can decrease the 
amount absorbed and effects of several ARV drugs. For example, in the case of didanosine 
(buffered tablet and enteric-coated granules within capsules), it is recommended to take it 
on an empty stomach (2 hours before or two hours after meals), (la Porte et al., 2005) 
because a decrease (between 18 and 55%) in the amount absorbed can be produced (level 3: 
risk medium). (Damle et al., 2002c; Kearney et al., 2005) Such effect may be minimized if 
didanosine is administered in combination with indinavir/ritonavir or with tenofovir (La 
Porte et al., 2005; Kearney et al., 2005) (see didanosine- tenofovir Interaction below).  
3.5.2 Interactions related to presystemic metabolism and/or P-glycoprotein activity 
P-gp (ABCB1) is one of the most extensively studied transporters regarding DIs. P-gp is 
expressed in multiple key organs in drug disposition such as small intestine, blood-brain 
barrier, kidney, and liver. Therefore, P-gp mediated DIs can occur at various organs and 
tissues. Thus, the induction or inhibition of P-gp can lead to drug-drug interactions. For 
instance, induction of the intestinal P-glycoprotein activity can cause reduced bioavailability 
of orally administered drugs and cause therapeutic failure. In contrast, the inhibition of the 
intestinal P-gp activity can lead to increased bioavailability, concentrations and adverse 
drug effects. (Josephson, 2010) 
Broadly, PIs, particularly ritonavir, are mechanism-based intestinal P-gp efflux activity 
inhibition, which partially explains the effect on the levels and clinical results of some drugs, 
(de Maat et al., 2003) such as cyclosporine (Izzedine et al. 2004) and digoxin. (Penzak et al., 
2004) Ritonavir can also inhibit renal P-gp activity, which may lead to a decrease in renal 
clearance of digoxin, associated with an increase in the levels and effects of this drug. (Ding 
et al., 2004)  
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Simultaneous administration of saquinavir 500 mg (low dose ritonavir) with omeprazole is 
associated with an increase of 82% in AUC of saquinavir. Although the mechanism is 
unclear, it is believed that this effect is due to the fact that omeprazole can inhibit P-gp 
activity and other membrane transporters activity. (Winston et al., 2006) Similarly, 
saquinavir bioavailability increases significantly when administered with cimetidine, 
(Boffito et al., 2002) ranitidine or food, an effect independent of pH increase. (Kakuda & 
Falcon, 2006) These findings could lead to believe that food is likely to increase solubility 
and to decrease the hepatic first pass effect, while the effect of cimetidine, ranitidine, and 
omeprazole, similar to what has been observed with other known inhibitors of intestinal 
and hepatic CYP3A4, may be associated to decreased presystemic metabolism and, to a 
lesser extent, to decreased P-gp intestinal activity. (Amariles, 2007) 
4. Clinically relevant pharmacodynamic drug interactions in HIV-infected 
patients receiving antiretroviral therapy 
Due to it is important some examples related to pharmacodynamic DIs in HIV-infected 
patients are detailed: 
 Lamivudine and emtricitabine: this combination is considered inadequate, since these 
drugs show a minimum additive effect, as well as a similar profile of resistance (DHHS, 
2011) (level 2: high risk). 
 Stavudine and zidovudine: this combination is considered inadequate, because their 
chemical similarity can lead to competition for intracellular phosphorylation 
zidovudine inhibits phosphorylation and effects of stavudine (Ray, 2005) which might 
cause therapeutic failure (Level 2: high risk). Concerning this interaction, it is important 
to note that prior exposure to zidovudine (2 to 45 months) does not influence the ability 
of HIV-infected patients to phosphorylate stavudine. (Hoggard et al., 2001) Due to 
similar mechanism, the lamivudine and zalcitabine combination is considered 
inadequate, since lamivudine may inhibit the phosphorylation of zalcitabine, which 
may lead to therapeutic failure (Becher et al., 2004; DHHS, 2011; Havlir et al., 2000) 
(level 2: high risk). 
 Abacavir, tenofovir, and lamivudine (or emtricitabine) as a triple NRTI therapy: This 
combination is considered contraindicated due to the rapid onset of virologic failure, 
when used as initial therapy (level 2: high risk). (DHHS, 2011) A similar consideration 
has been established for combination of tenofovir, didanosine, and lamivudine 
(emtricitabine). (DHHS, 2011)  
 Amprenavir and fosamprenavir: This combination is not recommended, because 
fosamprenavir is a prodrug of amprenavir, thus their combined use increases the risk of 
adverse drug reactions without additional benefits (level 2: high risk).(DHHS, 2011) 
 Stavudine and aminopterin: This combination is not recommended, because the 
combination causes an inhibition of hepatic mitochondrial DNA and hepatic toxicity 
(Setzer et al., 2008) (level 1: very high risk).  
 Tenofovir and cisplatin or pemetrexed: The use of tenofovir in patients receiving 
cisplatin or pemetrexed may increase the risk of renal toxicity (3: medium risk). 
(Makinson et al., 2010)  
 Tenofovir/emtricitabine, disulfiram and nifedipine: The use of nifedipine in HIV-
infected patients receiving tenofovir/emtricitabine and disulfiram may cause lactic 
acidosis (level 2: high risk). ( Moling et al., 2009) 
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 Zidovudine, cisplatin or pemetrexed: The use of zidovudine in patients receiving 
cisplatin or pemetrexed may increase the risk of hematological toxicity (Makinson et al., 
2010) (level 3: medium risk). 
 Broadly, the use of drugs with a similar unsafe profile leads to an increased probability 
and severity of adverse effects, for instance: 
 Stavudine and didanosine: This combination is considered absolutely 
contraindicated (level 1: very high risk), due to increased likelihood of significant 
synergism of adverse drug problems associated with mitochondrial toxicity, which 
may manifest, especially as peripheral neuropathy, pancreatitis, and lactic acidosis. 
(Boubaker et al., 2001; Catanzaro et al., 2004; Coghlan et al., 2001; DHHS, 2011)  
Similarly, didanosine/zalcitabine and stavudine/zalcitabine combinations are 
considered contraindicated because of a greater likelihood and severity of 
peripheral neuropathy (Dalakas et al., 2001; Simpson & Tagliati, 1995) (level 1: very 
high risk). In general, NRTIs (lower risk with abacavir and lamivudine) may inhibit 
competitively the mitochondrial DNA polymerase gamma, an enzyme responsible 
for repairing mitochondrial DNA associated with oxidative alterations. (Dagan et 
al., 2002) Therefore, the use of NRTI may lead to depletion of DNA and 
uncoupling of mitochondrial respiratory chain and thus, to the accumulation of 
radicals and free fatty acids, as well as dicarboxylic acids, responsible for 
mitochondrial toxicity associated with this group of drugs. (Petit et al, 2005) 
 Zidovudine and ganciclovir: This combination increases the likelihood of 
developing bone marrow suppression, a condition associated with the occurrence 
of severe hematologic toxicity and life threatening infections, including the 
progression of cytomegalovirus infection (Hochster et al., 1990) (level 1 : very high 
risk). Related to this type of interaction, another combination with additive 
hematologic toxicity combination is zidovudine with ribavirin, associated with an 
increased risk of anemia (DHHS, 2011) (level 2: high risk). 
 Didanosine and ribavirin. This combination increases the likelihood of mitochondrial 
toxicity, which can lead to lactic acidosis and pancreatitis (Fleischer et al., 2004; 
Perronne et al. 2006) (level 2: high risk). Similarly, the didanosine-adefovir 
combination increases the risk of pancreatitis (Perronne et al. 2006) (level 2: high risk). 
 Atazanavir and indinavir: This combination increases the likelihood of developing 
hyperbilirubinemia (DHHS, 2011) (level 2: high risk). 
 Drugs with additive hepatic toxicity: In general, concomitant use of hepatotoxic 
drugs enhances the probability of hepatic alterations, for instance, when rifampicin 
is used with isoniazid (Steele et al., 1991) or with pyrazinamide (Yee et al., 2003) for 
treatment of tuberculosis; or when acetaminophen is used with zidovudine 
(Shriner & Goetz, 1992) (Level 2 or 3: high or middle risk). 
 Drugs with additive renal toxicity: Simultaneous use of renal toxic drugs increases 
the likelihood of problems in this organ, for instance the simultaneously use of 
adefovir, acyclovir (intravenously), cidofovir, foscarnet, indinavir, ritonavir, 
tenofovir, pentamidine, aminoglycosides, and amphotericin B (Fisher et al., 1989) 
(level 2 or 3: high risk or middle). 
5. Clinically relevant drug-disease interactions in HIV-infected patients 
receiving antiretroviral treatment  
Due to it is important some examples related to clinically relevant drug-disease interactions 
in HIV-infected patients are detailed: 
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 Pregnancy 
 Amprenavir oral solution, due to the high content of propylene glycol, as an 
excipient, can cause toxicity problems (DHHS, 2011) (level 2: high risk). 
 Efavirenz, especially during the first 3 months, because it represents a potential 
teratogenic risk, it is included in the D category of FDA classification of drugs for 
teratogenic risk (AIDS Patient Care, 2005; DHHS, 2011) (level 2: high risk).  
 Didanosine and stavudine, because there are reports of severe and even fatal lactic 
acidosis in pregnant women receiving stavudine and didanosine (DHHS, 2011) 
(level 2: high risk).  
 Moderate (Child Pugh score: 7-9 points) or severe (Child Pugh: over 9 points) liver 
failure   
 NNRTI and PI. In general this class of drugs should be administered with caution 
or avoided altogether in patients with moderate or severe liver failure (DHHS, 
2011) (level 3: medium risk). 
 Amprenavir, fosamprenavir. Avoid their use in the presence of severe liver failure 
(Amariles et al., 2007c; DHHS, 2011) (level 3: medium risk). 
 Amprenavir/ritonavir, tipranavir / ritonavir. Their use is contraindicated in severe 
liver failure (Amariles et al., 2007c; DHHS, 2011) (level 2: high risk). 
 Children under 4 years. Amprenavir oral solution. Due to the high content of 
propylene glycol, as an excipient, it can cause toxicity problems (DHHS, 2011) (level 2: 
high risk). 
 Women with CD4 lymphocyte counts> 250 cells/mm3 or men with CD4 lymphocyte 
counts > 400 cells/mm3. For these groups of patients there are reports of serious, 
sometimes fatal, liver impairments attributed to nevirapine (DHHS, 2011) (level 2: high 
risk). 
 Cirrhosis. The combination of didanosine and ribavirin can lead to liver 
decompensation. Therefore, this combination is considered no-adequate for patients 
with advanced liver fibrosis (Perronne, et al. 2006) (level 2: high risk). 
 HIV. The use of rifapentine (rifamycin) is considered inadequate, due to fewer 
efficacies in preventing the onset of tuberculosis in this group of patients. For this 
reason this could be considered as a possible drug-disease interaction (DHHS, 2011) 
(level 2: high risk). 
6. Other clinically relevant drug interactions in HIV-infected patients 
attributed to different or unclear mechanisms 
Other examples of clinically relevant DIs in HIV-infected patients attributed to different or 
unclear mechanisms are: 
 Zidovudine and enzyme inducers. Zidovudine is metabolized and inactivated by 
glucuronyl transferase. Thus, inducers or inhibitors of this enzyme can affect its levels 
and effects (Kiang et al, 2005). For example, rifampicin may increase zidovudine 
metabolism and decrease its levels and effects. (Gallicano et al., 1999) 
 Tenofovir and didanosine. Tenofovir increases didanosine levels and toxicity 
(particularly, pancreatitis), (Martinez et al., 2004) apparently due to inhibition of its 
metabolism by purine nucleoside phosphorylase. (Ray et al., 2004) It is thus 
recommended to reduce the dose from 400 mg to 250 mg/24 hours in patients weighing 
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less than 60 kg. (Kearney et al., 2005; Martinez et al., 2004; Antoniou et al., 2003) 
Additionally, even using reduced dose, didanosine toxicity signs and symptoms should 
be monitored (significant increase in serum amylase or lipase, neuropathy, paresthesia, 
nausea, vomiting, and abdominal pain). (DHHS, 2011) There are reports of didanosine 
toxicity (deadly lactic acidosis and acute hepatic failure), (Guo &  Fung, 2004; Masía et 
al., 2005) at doses of 200 mg/day, especially in women weighing 60 or less kg. A similar 
effect could be observed when administering didanosine with other purine nucleoside 
phosphorylase inhibitory drugs, such as allopurinol, ganciclovir (Moling et al., 2009) 
and valganciclovir. (Tseng & Salit, 2007) Additionally, the use of didanosine-tenofovir 
combination may lead to decrease in the CD4 lymphocyte levels, thus this combination 
should be avoided (Anderson & Kakuda, 2006; Barreiro & Soriano, 2006) (level 1 or 2: 
Very high risk" or higher). Similarly, the didanosine and ganciclovir combination has 
also been associated with decreased CD4 cell levels (Tseng & Salit, 2007) (level 2: high 
risk).  
 Amprenavir oral solution (propylene glycol) and oral ritonavir (ethanol excipient). 
Because propylene glycol and ethanol are metabolized by the same enzyme, 
accumulation and toxicity may occur. (DHHS, 2011) Also, related to the presence of 
excipients, the use  of lopinavir/ritonavir oral solution (4.2% in ethanol) combined with 
metronidazole or disulfiram, substances that may inhibit the alcohol dehydrogenase, 
may lead to the development of disulfiram effect. (Cvetkovic & Goa, 2003; de Maat et 
al., 2003) 
 Atazanavir and tenofovir. Tenofovir reduces atazanavir levels through a mechanism still 
to be established, so it is recommend using atazanavir (300 mg) together with low dose 
ritonavir (100 mg) as an enhancing agent. (Taburet et al., 2004) In addition, 
lopinavir/ritonavir and atazanavir may increase levels and toxic renal effects of tenofovir. 
(Perronne et al., 2006) It is important to illustrate that the inductive effects of tenofovir on 
the metabolism of atazanavir have not been documented to others PIs (Boffito et al., 2005) 
 Saquinavir and adefovir. Adefovir (antiviral used in the treatment of hepatitis B) 
lowers saquinavir levels and effects. (Perronne et al. 2006) 
 Tenofovir and enzyme inducers. NRTIs with inducing capacity (efavirenz and 
nevirapine) (Droste et al., 2006) and probably rifampicin, (Droste et al., 2005) do not 
cause variation in tenofovir levels and effects. Therefore, it is not recommended to 
adjust the dose of either drug, when it is necessary to use such combinations. 
 Amprenavir capsules, vitamin E, and warfarin levels. Amprenavir capsules contain an 
amount of vitamin E that exceeds recommended daily dose, so in patients treated with 
amprenavir in this dosage form, vitamin E supplementation should be avoided. In 
patients under treatment with warfarin, high levels of vitamin E (associated with 
intakes higher than 400 IU per day) increase the risk of bleeding. (Amsay et al, 2005, 
Heck et al., 2000) 
 Strong or moderate inhibitors and PIs. Some known enzyme inhibitors such as 
ketoconazole may decrease the extra-intestinal P-gp efflux activity and increasing PIs 
levels and effects in certain body areas, such as the cerebrospinal fluid, which have been 
evidenced for ritonavir and saquinavir. (Cvetkovic & Goa, 2003; Oldfield & Plosker, 
2006; Lin & Yamazaki, 2003; Lin, 2003; Khaliq et al., 2000) 
 Rosiglitazone and nevirapine. Rosiglitazone, apparently due to increased CYP3A4 or 
P-gp activity, may decrease nevirapine levels. This effect does not occur when using 
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lopinavir/ritonavir with nevirapine. (Oette et al., 2005) Thus, it is recommended to 
monitor nevirapine levels and effects, when this drug is used in combination with 
rosiglitazone (level 2: high risk). 
 Maraviroc and raltegravir. The concomitantly administration of these drugs can reduce 
peak concentrations of both drugs due to changes in pre-systemic elimination associated 
to changes in absorption and/or first pass metabolism; however, the exact mechanism of 
interaction has not been determined (Andrews et al., 2010) (3: medium risk). 
7. Software for evaluating and predicting clinical relevance of drug 
interactions in HIV-infected patients receiving antiretroviral therapy 
The identification, systematization, evaluation, and prediction of DIs may be easier by using 
computer applications. Additionally, these kinds of informatics tools may contribute to 
reduce the risk to arise of clinical relevant DIs, and thus, the negative effect in goals of 
HAAR or cART in patients with HIV/SIDA. Thus, the design software that facilitates the 
identification and prediction the clinical relevance of drug interactions may be an important 
contribution to get the possible outcomes best in HIV-infected patients receiving HAART or 
cART. (Amariles et al., 2008) In this way, the following tasks have been done: 
a. Structured and systematic review of publications on Pubmed/Medline and other 
electronic databases, supplemented by other primary and secondary information 
sources to identify DIs in HIV-infected patients receiving ART therapy. Thus, 
published articles of DIs in HIV-infected patients were identified by a comprehensive 
literature search using electronic databases of information sources (Medline/Pubmed, 
SIETES, Medscape, and Tripdatabase) to identify all full text or abstracts published in 
English and Spanish from January 1996 to February 2011. Additionally, a search was 
done in some specify journals: New England Journal of Medicine, British Medical 
Journal, and other recognized information sources: the electronic sheet drug 
interactions: www.drug-interactions.com; Philip D. Hansten, John R. Horn. Managing 
Clinically Important Drug Interactions, facts and comparison, 2003; Stockley IH. Drug 
Interactions. First edition. Pharma Editores. Spain, 2004, and Drug Interaction Facts, 
Micromedex (Drug-REAX) computer program.  
b. Classification of the clinical relevance of pairs of the identified DIs. The accessing 
and predicting the clinical relevance of pairs of the identified DIs were based on the 
severity and probability of occurrence of the DIs. Based on the possible combinations of 
severity and probability of occurrence, DIs were grouped into 4 categories: Level 1 
(very high risk), level 2 (high risk), level 3 (medium risk), an level 4 (low risk) as it was 
mentioned in numeral 2.3 (Determining and predicting of the clinical relevance level) 
(Amariles et al., 2007a)  
c. Software design. The results of the review and evaluation of clinical relevance of the 
DIs were used to design a platform with alert generator, report generator, constant 
evolution support systems data integrity, network management intranet and Internet 
Web and Windows platforms. The developed software facilitates the identification, 
evaluation, and prediction of clinical relevant of 1,082 drug pairs of potential DIs, near 
to 80% of them due to pharmacokinetic mechanism (changes in plasma concentration), 
mainly associated to enzyme inhibition. The scaling of these 1,082 drug pairs of the 
recognized DIs according to different dosage forms and strengths of identified drugs, 
generates a total of 6,087 pairs of DIs, which, according their clinical relevance, 4,158 
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(68.3%) are clinical relevant (Levels 1 and 2) in HIV-infected patients receiving ARV 
therapy. Thus, the software meets the requirements defined for this type of programs. 
(Gaikwad et al., 2007; Rodríguez et al., 2009)  
d. Software implementation. The program, posterior to entering drug treatment of a 
specific patient, generate the list of possible interactions with clinical relevance, 
accompanied by the suggestion of the most appropriate process to be followed by the 
healthcare professional user of the program. In Colombia, the program have been 
implemented in 24 health institutions, in addition the access is free and it is available on 
the website http:www.udea.edu.co/pypfarmaceutica. However, further investigation to 
evaluate in more detail information regarding to positive predictive and negative 
predictive values of alert generates by program is required. 
8. Conclusions  
Due to ARV therapy is one of the most dynamic in terms of launching new products in the 
market, it is necessary to carry out structured and systematic review of publications on 
Pubmed/Medline and other electronic databases to identify new DIs in HIV-infected 
patients, receiving ART therapy, which must be complemented with evaluating the 
scientific evidence and classifying their clinical relevance. 
In HIV-infected patients receiving antiretroviral therapy, closer to 80% of relevant clinical 
pharmacokinetic DIs are associated to induction or inhibition of the systemic hepatic 
metabolism, which is associated to systemic clearance for a significant number drugs. While 
closer to 20% of relevant clinical pharmacokinetic DIs are associated to changes in 
bioavailability related interactions, including changes in gastrointestinal pH, presystemic 
metabolism and/or P-gp transport activity. Therefore, in HIV-infected patients receiving 
HAART of cART, the assessing and predicting clinical relevance of a given pharmacokinetic 
DI need to understand and use of concepts related to induction and, particularly with 
enzyme inhibition (mainly in CYP3 and CYP2 subfamilies) and, to a lesser extent, to 
bioavailability (especially with changes in a drug presystemic metabolism and/or P-gp 
transport activity).  
It is becoming more evident that ARV drugs are metabolized via common pathways by 
CYP450 enzymatic complex, which leads to an increased probability of new clinical relevant 
pharmacokinetic DIs due to the inhibition or stimulation of CYP isoforms (mainly in CYP3 
and CYP2 subfamilies). 
In general, for a patient using more than one drug with differential capacity to modify 
CYP3A4 and/or P-gp enzymatic activity (some induce while some others inhibit), it is 
difficult to predict the net effect on the levels and effects of a drug whose metabolism is 
affected. (Spradling et al., 2002) Therefore, it is necessary, from a theoretical perspective, to 
avoid the use of such schemes, which is difficult in patients with HIV/AIDS. In this context, 
some studies conducted to establish the influence of several antiretroviral drugs on CYP3A 
activity show that ritonavir/nelfinavir inhibitory effect is maintained and it counteracts 
efavirenz/nevirapine inducing effect, when they are administered in combination. 
Additionally, it has been found that chronic administration of ritonavir (200 mg/day) or 
nelfinavir (2.5 g/12 hours) does not increase CYP3A activity. (Fellay et al., 2005; Mouly et 
al., 2006) 
Similar to other groups of patients, it is important to systematize, distribute, and use 
guidelines and recommendations based on the findings of studies indicating which 
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combinations of a specified drug, of some specify therapeutic class, are the most appropriate 
for patients receiving cART or HAART. Such appropriate combinations should be chosen 
considering the lowest probability of the DIs, which should lead to a decrease in the use of 
less adequate combinations, as evidenced by studies in other countries. (Hulgan et al., 2005) 
The developing software based both on the severity of the effect, and on the probability of 
occurrence of a specify DI, including quality and quantity of literature that supports the 
interaction (evidence) in order to establish its clinical relevance, could be a notable 
contribution to the management of DIs in VIH-infected patients receiving ARV therapy. 
Since proprietary databases and clinician assessment of severe DIs do not agree, developing 
a knowledge base for a DI alert system likely requires proprietary database information in 
conjunction with clinical opinion. (Smithburger et al., 2010) Thus, evaluation and prediction 
of relevant clinical DIs involves not only using DI alert system, but also the clinical 
interpretation of the alert and information, including drug history and the patient's clinical 
condition. In this task, a computer program that facilitates the evaluation, prediction, and 
decision on the clinical relevance of the DIs in HIV-infected patients receiving ART therapy 
have been designed, however its clinical utility requires be assessed in a study designed for 
this goal.  
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